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CHAPTER 1 
General introduction 

Malaria is an infectious disease transmitted by mosquitoes and is caused by 
parasitic protozoa of the genus Plasmodium. The parasite occurs in different 
forms which have successfully adapted to different cellular environments, 
both in the vertebrate host and the mosquito vector. Over 100 species of 
Plasmodia infect rodents, birds and primates (1-3). 
Throughout history malaria has plagued travellers to the tropics and is even 
recorded in ancient Asian and Chinese writings (1). Nowadays, in almost all 
tropical areas malaria is endemic (1,4). More than 400 million people are 
estimated to be infected and each year the disease causes up to 2 million 
deaths of which the majority are children (1,4). The wide distribution of 
malaria is attributable to the adaptability and breeding potential of the 
Anopheles mosquito. Four species of Plasmodium infect man, i.e. 
Plasmodium vivax, P. ovale, P. malariae and P. falciparum. The first three 
cause moderate to severe illness and are seldom fatal. The fourth type of 
malaria parasite, i.e. P. falciparum, to which the greatest attention is paid in 
investigations, causes much more serious and progressive illness and 
frequently leads to coma and death (1,2,5). P. falciparum is particularly 
dangerous to children between one and five years old, and to travellers from 
non-endemic areas. 
During the last decades malaria control strategies have relied both on 
insecticides against the mosquito vector and on anti-malaria drugs used as 
prophylaxis or as treatment. These drugs and insecticides developed at great 
cost tend to lose their value as the parasite and/or the mosquito population 
becomes gradually resistant to these 'antimalarials' (6,7). Resistance to the 
drugs is spreading rapidly in most tropical areas. To give an example, in 
South-East Asia strains of P. falciparum are resistant to most if not all drugs 
in use. To circumvent these problems, from the mid-1970s the strategies to 
control malaria have been directed at the development of effective vaccines. 
This strategy has been highly recommended and supported by the WHO (8-
11). It is clear that for the achievement of this goal a large number of 
obstacles have to be overcome. The use of attenuated or killed parasite 
preparations as a vaccine is not a realistic approach because of problems 
associated with parasite supply, the danger of transmitting other pathogens 
with the inoculum and the possible development of autoimmunity due to the 
almost inevitable contamination of host antigens in the preparation (12). 
Fortunately, the rapid advances in recombinant DNA technology, peptide 
chemistry and immunology have in theory provided powerful tools and novel 
approaches to achieve this goal (8-11). Development of an effective synthetic 
or recombinant vaccine against malaria, however, has been slower than some 
have anticipated. There are several major obstacles to produce an effective 
malaria vaccine. One of these is the incomplete knowledge of man's immune 
response to the malaria parasite. The immune response to plasmodia is very 
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complex and the respective roles of humoral and cellular immunity and 
specific and non-specific immune responses in the development of resistance 
to malaria in man are only partly elucidated (13-21). Immunity to malaria 
can be established under natural conditions, but it involves repeated 
infections, takes years to develop and is usually of short duration. Sterile 
immunity is rarely achieved. Adults living in areas of high transmission are 
protected by a form of partial immunity called premunition; parasitemia 
mostly persists in the absence of clinical disease. 
Plasmodia have developed mechanisms of (partially) escaping the protective 
effector mechanisms of their hosts. One of these escape mechanisms and 
probably the major reason for the laborious development of an effective anti-
malaria vaccine is the complex life cycle of the parasite, comprising several 
stages which are morphologically, biochemically and antigenically distinct 
(3,8,10,22,23). The life cycle of the P. falciparum parasite is schematically 
drawn in Fig. 1. Malaria infection starts with a bite by an infected female 
Anopheles mosquito which injects P. falciparum sporozoites into the 
bloodstream during feeding. Sporozoites rapidly migrate to the liver where 
they invade liver cells. Once within the hepatocytes, the parasites transform 
into pre-erythrocytic schizonts, leading to the development of thousands of 
merozoites per infected cell. When these merozoites are released, they 
immediately invade erythrocytes where they develop into erythrocytic 
schizonts. The erythrocytic schizonts develop to merozoites and release of 
these merozoites by rupture of the infected red blood cell reinitiates the 
erythrocytic cycle. It is this erythrocytic cycle which is responsible for the 
clinical manifestations of the disease. Within the red blood cell, some 
merozoites differentiate into another morphologically distinct form called 
gametocytes, a sexual stage with male and female forms. 
Fig 1 Life cycle of the human malaria parasite Plasmodium falciparum 
Sporozoites (A) are the infective stage of the parasite found m the salivary glands of female Anopheles 
mosquitoes They are injected into the host's circulation by feeding mosquitoes Sporozoites rapidly migrate 
to the liver where they invade liver cells and become tissue schizonts (B), leading to the development of 
thousands of merozoites On release from the liver into the bloodstream, the merozoites (C) invade 
erythrocytes and become erythrocytic trophozoites (D) Throphozoites in turn develop into multinucleated 
schizonts that give rise to merozoites (E) that are released by rupture of the infected red blood cell These 
merozoites invade other erythrocytes, thereby completing the erythrocytic cycle Some merozoites develop 
intracellular^ to form male and female gametocytes (F) When these gametocytes are ingested along with 
the bloodmeal by mosquitoes they develop after emerging from the human host's erythrocyte in the 
mosquito midgut into male and female gametes (G) Fertilisation to form the zygote takes place immediately 
after exflagellation (H) The fertilised zygote transforms to a motile ookinete (I) and glides to the cells 
lining the stomach wall At the stomach wall the ookinete penetrates through or between the epithelial cells. 
The ookinete comes to rest between the stomach epithelial cells and their basement membrane where it 
develops into an oocyst (J) Within the oocyst thousands of sporozoites are formed (K) which, upon rupture 
of the oocyst, then migrate via the haemocoel to the salivary glands 
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When sucked up in a blood meal by a feeding mosquito, gametocytes 
differentiate in the mosquito midgut into male and female gametes, thereby 
emerging from the host's erythrocyte. After fertilisation, the zygote 
differentiates into a motile ookinete and glides to the cells lining the stomach 
wall. At the stomach wall the ookinete penetrates through or between the 
epithelial cells. The ookinete comes to rest between the stomach epithelial 
cells and their basement membrane where it develops into an oocyst. Within 
this oocyst sporozoite formation takes place resulting in the formation of 
thousands of sporozoites which, upon rupture of the oocyst, migrate via the 
haemocoel to the salivary glands of the mosquito. 
A parasite most probably escapes from a protective immune response 
directed against a particular life cycle stage via transformation into another 
stage (5,8-11,22,24). Effective vaccines should therefore preferentially 
induce protection against several or all developmental stages. Another 
possible escape mechanism of the parasite and a serious problem in designing 
an effective malaria vaccine is the antigenic diversity (polymorphism and 
variation) in malaria parasites. Diversity is not only found between isolates 
but also within isolates (25-27). The search for protective antigens has also 
been complicated by the observation of multiple crossreactivities between 
different parasite proteins, which may assist the parasite by diverting the 
immune response towards irrelevant epitopes generally known as 
'smokescreen' effect (28,29). Mimicry of host sequences by the parasite may 
also be one of the strategies of the parasite to reduce immune effective 
mechanisms of the host (30). This molecular mimicry has also to be taken 
into account when developing a malaria vaccine. 
Despite all these obstacles, dramatic progress has been made in various areas 
of malaria research and vaccine development during the last decade and a 
large number of genes that code for stage specific vaccine candidate antigens 
have now been characterised (8-11). Although the most effective malaria 
vaccine is likely to be composed of antigens from several stages to block the 
parasite at various points in the life cycle, in the following paragraphs four 
types of malaria vaccines directed to different developmental stages will be 
discussed; namely those targeted to sporozoites, the liver stages, the blood 
stages and those that block transmission of the parasite by immune 
interference with the development of the sexual stages in the mosquito. 
Sporozoite-blocking vaccines 
The purpose of a sporozoite vaccine is to prevent infection via blocking of 
invasion of the liver by the parasite (31). Studies on rodents, monkeys and 
humans have shown that protection can be achieved by repeated bites with 
infected mosquitoes or by intravenous injection of irradiated sporozoites (31-
33). Several observations have demonstrated that the protective immunity 
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achieved after immunisation with irradiated sporozoites was, at least in part, 
antibody mediated and that the protective antigen is present on the surface of 
sporozoites (15,27,31). Protection was stage- and species-specific (15,31). A 
volunteer who resisted two challenges with P. falciparum sporozoites 
developed malaria when injected with its blood stages or following challenge 
with P. vivax sporozoites (31). Protection against various geographical 
isolates and strains of the homologous species has also been observed (31). 
Because it is technically impossible to produce sufficient sporozoites for 
large scale immunisations, research has been focused on the identification of 
the relevant sporozoite antigens. Since immunisation with sporozoites 
involves humoral (32) and cellular (34-38) immune responses against the 
circumsporozoite (CS) protein, the CS protein has been the focus of most 
efforts to develop a pre-erythrocytic stage malaria vaccine. Sporozoites are 
completely enveloped by a thick surface coat consisting of the 
circumsporozoite (CS) protein and studies have revealed many similarities 
among CS proteins of various species of malaria sporozoites (10,31,39,40). 
CS proteins were shown to have immunodominant repetitive epitopes flanked 
by non-repetitive regions (31). Unfortunately, it has not been possible to 
induce protective immunity with recombinant or synthetic vaccines based on 
CS protein only (15,41-46). Recent studies strongly suggest that other 
antigens than the CS protein, like TRAP and Pfsl6, present on the 
sporozoite surface, may be involved in the induction of protective immunity 
(47-50). 
Although results of early epidemological studies suggested that antibodies to 
sporozoites play an important role in naturally acquired immunity to malaria 
(31) the strategies to develop a malaria sporozoite vaccine are now focusing 
more and more on the induction of cellular immunity, because a number of 
studies on the role of Τ cells in malaria immunity have shown that these cells 
are critical for the development of immunity (21,27,35,51,52). The targets of 
these Τ cells however are not sporozoites but the subsequent developmental 
stages of the parasite in hepatocytes. 
Vaccines against the liver stages 
The liver stage parasites represent another attractive point of immune attack, 
because antigen-specific cellular effector mechanisms have recently been 
shown to operate during killing of infected hepatocytes by either CD8+ or 
CD4+ cytotoxic Τ lymphocytes (CTL) (12,15,36,37,53,54). Hepatocytes 
express major histocompatibility complex (MHC) class I antigens and can be 
induced to express MHC class II antigens (12,55). CTLs appear to exert the 
destruction of intra-hepatocytic parasites by a mechanism which involves 
close cell-to-cell contact (12). Although some major advances in in vitro 
assays have been made to study vaccine candidates against the liver stages 
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(56,57), identification of 'protective' antigens is, however, extremely 
difficult particularly because even nowadays small amounts of infected 
starting material are difficult to obtain. Despite of this, one already has 
succeeded in the identification of a few liver stage antigens (49,58-60). 
Although liver stage parasites do share antigens with both sporozoites (CS 
protein) and asexual stages (MSA 1 antigen), they appear to be antigenically 
distinct (10,11,28). It is clear that this property is of great advantage for 
vaccine development, because, as a result of this, parasites that escape the 
anti-sporozoite immune response are still vulnerable to immune attack while 
developing in the liver stages. The first antigen that has shown to be a target 
for human CTLs in the liver is the CS protein of P. falciparum (38). CTL 
specific for the CS protein were shown to be present after immunisation of 
human volunteers with irradiated sporozoites of P. falciparum (34,38). When 
peripheral blood mononuclear cells (PBMC) from volunteers immunised with 
irradiated P. falciparum sporozoites were stimulated in vitro with a 
recombinant vaccinia virus expressing the P. falciparum CS protein, the 
PBMC lysed autologous Epstein-Barr virus-transformed В cells transfected 
with the P. falciparum CS protein gene. Activity was antigen specific, 
genetically restricted and dependent on CD8+ Τ cells. However, the CTL 
response to the CS protein was demonstrated to be very low under conditions 
of natural exposure (61). This may be caused by several factors, as proposed 
by Doolan et al. (61): (A) the large number of naturally occur ing varieties of 
the CS protein; (B) the inability to generate specific CTL to all the different 
isolates; (C) the low rate of natural exposure (compared with laboratory 
situations); (D) genetic non-responsiveness; or (E) the apparent requirement 
for recent sporozoite exposure to maintain CS protein-specific CTL. Natural 
infection may, however, elicit CTL to non-CS protein malarial antigen, such 
as TRAP (SSP2), which may act in concert with CS protein-specific CTL 
(51,61) or the liver stage-specific antigen 1 (LSA-1), since this antigen 
shares some sequence homology with the CS-protein CTL site (58,60). 
Interestingly, Hill and coworkers recently presented an epidemiological 
survey, conducted in an area in the Gambia with high malaria transmission, 
showing that the human leukocyte class I antigen HLA-Bw53, and an HLA 
class II haplotype (DRB1*1302-DQB 1*0501) are much more frequent in 
West Africans than in other racial groups and are independently associated 
with protection from severe malaria (62). They suggest that, since HLA class 
I molecules are absent from human red blood cells, CTL would probably act 
against the liver stage malaria parasites and that only individuals with the 
HLA class II haplotype (DRB1*1302-DQB 1*0501) are able to present a 
particular conserved epitope on a blood stage parasite antigen to helper Τ 
cells, leading to more rapid parasite clearance. 
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Vaccines against the asexual blood stages 
These developmental stages of the P. falciparum parasite are responsible for 
the severe morbidity and mortality associated with the disease (63). The 
asexual blood stages have been intensively studied and much of the progress 
in the characterisation of P. falciparum blood stage antigens has depended on 
the ability to grow these stages in vitro in automated cultivation systems 
(64). Natural immunity to the asexual erythrocytic stages of P. falciparum 
appears to be acquired gradually following repeated infections (65,66). 
Antibodies play an important role in protection, but Τ cells and cytokines 
almost certainly also play a major role in immunity to blood stage malaria 
parasites (10,12,64,65). Candidate antigens for vaccine development have 
been identified on the surfaces of the merozoites and the infected red blood 
cells and among the proteins that are secreted by the parasite (5,8-11,14,67). 
One of the most prominent candidates for the development of an asexual 
blood stage vaccine is the major merozoite surface antigen 1 (MSA 1) from 
which three related processing products have been identified (68-71). 
Immunisation of Saimirí or Aotus monkeys with MSA 1 induced (partially) 
protective immunity (70,72,73). Another antigen generally considered as a 
major candidate for the development of a blood stage vaccine is PÍ155/RESA 
(26,74-76). This antigen is discharged from merozoite micronemes during 
invasion and becomes anchored to the erythrocyte cytoskeleton. 
Immunisation of monkeys with this protein induced partial resistance to 
challenge with P. falciparum (77,78). Besides RESA and MSA 1, a number 
of other molecules of the asexual blood stages have been identified to which 
a potential protective value has been attributed (5,8-11,14,63,64,73,79-81). 
This group of antigens includes antigen-1, p82, RAP-1, CARP, Pf72/Hsp70-
1, SERA and MSA2. Vaccination trials in monkeys and human volunteers 
against blood stages of P. falciparum with a synthetic vaccine, SPf66, were 
reported lately by Patarroyo and coworkers (82-84). This vaccine is a 
copolymer of short peptide sequences derived from three different 
erythrocytic stage malarial antigens. One polypeptide represents eleven 
amino acids of the MSA 1 protein. The sequence of the two other peptides 
are derived from still incompletely characterised antigens 35.1 and 55.1. A 
sequence derived from the repetitive region of the CS protein has been used 
as a spacer to connect the individual peptides. The results seem promising, 
although complete protection has not been achieved (85). 
The existence of a parasitophorous duct that connects the parasitophorous 
vacuole with the red blood cell membrane has been described recently (86). 
This substructure might provide a new target or route for immunological 
attack against Plasmodium blood stages. 
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Transmission-blocking vaccines 
A transmission-blocking vaccine induces the formation of antibodies which, 
when ingested by the mosquito, block or impair the (sexual) development of 
the malaria parasite and consequently its transmission (87,88). In several 
species, transmission blocking immunity has been induced via immunisation 
with gametes (89,90). Candidate antigens for the development of a 
transmission-blocking malaria vaccine are proteins associated with the sexual 
cycle of the parasite (5,8-11,14,87,88). Much of the effort to develop 
transmission-blocking vaccines has focussed on the three sexual stage-
specific antigens Pfs25, Pfs48/45 and Pfs230, because monoclonal antibodies 
(mAbs) against these antigens are able to prevent parasite development in the 
Anopheles vector, when fed to mosquitos via gametocytes-containing blood 
(92). Antibodies to Pfs230 and Pfs48/45 proteins have been found in human 
immune sera, whereas antibodies to the Pfs25 antigen have not (90,93). The 
absence of Pfs25 specific antibodies in human immune sera can be explained 
by the fact that the expression of the Pfs25 antigen only occurs in zygotes 
and ookinetes but not in gametocytes, the sexual stage which development 
occurs in the human host. The synthesis of the antigens Pfs230 and Pfs48/45 
is already initiated in developing gametocytes of P. falciparum two to three 
days after merozoite invasion of the red blood cell (88). However, the 
immune response to these proteins semes to be constrained in the human 
population. Genetic restriction at the human major histocompatibility 
complex (MHC) locus has been suggested (90). In a study of Riley et al. 
(93), however, malaria-exposed individuals with identical class II genotypes 
exhibited different cellular and humoral responses to the Pfs48/45 antigen, 
indicating that other explanations for non-responsiveness must be sought. 
The gene coding for antigen Pfs25 has been characterised and shown that the 
protein contains four epidermal growth factor (EGF)-like domains, each 
containing 5-6 cysteine residues (94). The Pfs25 antigen has been 
successfully expressed in recombinant vaccinia virus infected cells and 
immunisation of mice with recombinant vaccinia virus has shown to induce 
antibodies which blocked the infectivity of Plasmodium falciparum 
gametocytes to mosquitoes in membrane feeding experiments (95). A Pfs25 
analogue produced by a recombinant yeast was shown to react with 
transmission-blocking mAbs and to induce transmission-blocking immunity in 
experimental animals (96). The immunogenicity of the recombinant Pfs25 
polypeptides makes Pfs25 a promising transmission-blocking vaccine 
candidate. The genes coding for Pfs48/45 and Pfs230 antigens have been 
cloned and characterised very recently (97,98). However, until now, no data 
are available about the production and/or immunogenicity of recombinant 
polypeptides of these genes. 
20 
Conclusion 
Until recently, parasite material and primates used as animal models were 
difficult to obtain. Although the use of primates is still restricted, the 
development of in vitro cultivation methods and the achievements in 
molecular biology and peptide chemistry has opened new perspectives for the 
design of malaria vaccines. However, there are still a number of reasons 
why development of a malaria vaccine is still extremely difficult. Firstly, the 
vaccine should be produced in large quantities and in such a way that it 
fulfills the criteria for vaccines in general; it should be safe, efficient, easy 
to administer and cheap (10). Secondly, the complexity of the parasite's life 
cycle as well as antigenic diversity found among different strains severely 
hampers the development of an effective vaccine (99). Thirdly, many 
disappointing trials have been performed in the search for protective 
antigens, because of the fact that many of the molecules selected have 
immunodominant epitopes which, although capable of inducing the 
production of high antibody titers may not be the best targets for protective 
immunity (9,28,29). Fourthly, the complexity of the immune responses to 
Plasmodia makes it also very difficult to develop an effective malaria 
vaccine. Since both cell-mediated and humoral immune responses most 
probably contribute to acquired immunity in man, it is expected that a highly 
protective malaria vaccine has to result in induction of both specific Τ cells 
and antibodies. Two major subsets of Τ cells have to be induced: CD4+ and 
CD8+ cells. CD8+ cells will be needed for cytotoxic activity, whereas 
CD4 + cells are required for the inflammatory response by Thl cells and for 
the production of В cells to produce antibodies by Th2 cells. However, the 
epitopes recognised by В and Τ cells are usually distinct. This might have a 
great impact on future vaccination strategies as discussed by Perrin et al. (8). 
The number of Τ cell epitopes within an antigen tend to be small and is 
usually defined by continuous sequences of 7 to 15 amino acids. Moreover, 
the capacity for a host to respond to a given Τ cell epitope is generally 
restricted by genes of the major histocompatibility complex. В cell epitopes 
frequently depend on tertiary structures and therefore are composed of amino 
acids located at different positions in the protein structure. In contrast to 
antibodies, CD8+ cells are not usually obtained after immunisation with an 
intact protein. Studies are, however, in progress to construct vaccines that 
beside humoral responses also induce cell-mediated immune responses (15). 
Methods include the transformation of live vectors such as Salmonella, BCG 
and vaccinia with the relevant "protective" malaria genes (15). 
The field of malaria vaccines is currently very active with a large number of 
vaccine candidates derived from different developmental stages under 
investigation. It is likely that more vaccine candidate antigens will be 
identified in the near future. Improvement of the already existing vaccine 
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candidates may be achieved through the use of more potent adjuvants and 
efficient delivery systems such as liposome-associated immunogens, ISCOM 
particles and attenuated live vectors such as Salmonella and vaccinia virus 
(100-106). 
Outline of this thesis 
In this thesis studies with the aim to develop a vaccine against the human 
malaria parasite P. falciparum are presented. The strategy /methodology used 
for the isolation of a vaccine candidate is described in chapter 2. In this 
chapter we report the isolation of a novel gene of P. falciparum, Pfsl6, 
which is transcribed at very high rates in the sexual stages but not in the 
asexual erythrocytic stages of the parasite. From its nucleotide sequence it is 
deduced that the Pfsl6 gene encodes a protein of 157 amino acids 
(Mr= 16,607) which has all the characteristics of a surface protein. By using 
different experimental approaches, such as immunoblotting, 
immunofluorescence and immunoelectron microscopy, proteins reacting with 
Pfsl6 antigen specific polyclonal antibodies were found to be present in cells 
of sexual stages and sporozoites. The potential of the Pfsl6 antigen for the 
development of a transmission-blocking and/or sporozoite-neutralising 
vaccine is also discussed in chapter 2. In chapter 3 it is demonstrated by 
one- and two-dimensional Western blot analysis, using two Pfsl6 specific 
monoclonal antibodies, that the 16 kDa protein present in P. falciparum 
sporozoites is identical to the Pfsl6 antigen produced in sexual stage 
parasites. Moreover, firm evidence is presented that transcription of the 
Pfsl6 gene is regulated in a stage specific manner. 
Since it is generally agreed that antigenic diversity severely hampers the 
development of an effective malaria vaccine, the amino acid sequence 
diversity of Pfsl6 in P. falciparum isolates collected from different 
geographic areas have been analysed to assess the potential use of the Pfsl6 
antigen for a malaria vaccine. The results of this study are described in 
chapter 4A. Furthermore, a gene highly homologous to gene Pfsl6 was 
found to be present in P. reichenowi, a chimpanzee malaria parasite that is 
evolutionarily related to P. falciparum. Its nucleotide sequence is presented 
in chapter 4B. 
Because for basic research and vaccine development sufficient amounts of 
the Pfsl6 antigen can not be isolated from P. falciparum, recombinant Pfsl6 
sequences and peptides thereof have been produced in heterologous pro- and 
eukaryotic expression systems. In chapter 5A studies are presented on the 
induction in mice and rabbits of P. falciparum sporozoite-neutralising 
antibodies upon vaccination with recombinant Pfsl6 vaccinia viruses and/or 
recombinant Pfsl6 protein produced in yeast. Furthermore, in this chapter 
the use the recombinant vaccinia virus and the Pfsl6 protein produced in 
22 
yeast as a malaria vaccine is discussed. In chapter 5B the construction of a 
new system for the large-scale heterologous synthesis and one-step 
purification of antigen Pfsl6 in E. coli is described. It is shown that the 
recombinant protein is appropriate for large-scale epidemiological studies to 
demonstrate in human sera the occurrence of Pfsl6 specific antibodies. The 
recombinant Pfsl6 protein produced in yeast has also been used for the 
immunisation of different congenie mice strains to determine whether the 
Pfsl6 antigen is able to induce humoral as well as cellular immune 
responses. The results of this study are presented in chapter 6. 
In chapter 7 the consequences of multiple crossreactivities between different 
parasite proteins for vaccine development are discussed. 
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A novel protein antigen of the malaria parasite 
Plasmodium falciparum, 
located on the surface of gametes and sporozoites 
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ABSTRACT 
A Plasmodium falciparum cDNA clone was isolated of which the insert is transcribed at 
high rates as a 1.4-kb mRNA in the sexual stages of the malaria parasite. The cDNA 
clone contains a copy of a non-interrupted gene which codes for a protein of 157 amino 
acids (M
r
= 16,607). This 16 kDa protein does not contain repetitive sequences and is 
characterised by a putative N-terminal signal sequence, a hydrophobic membrane anchor 
sequence and a highly hydrophilic C-terminal region suggesting that this protein is an 
integral membrane protein. Rabbit antisera raised against a synthetic peptide covering 
amino acids 31-47 of the 16 kDa protein and against recombinant fusion proteins 
recognised the 16 kDa antigen in protein extracts of gametocytes, macrogamete/zygotes 
and sporozoites by Western blot analysis. The rabbit antisera also reacted with gametes, 
gametocytes and sporozoites in a standard immunofluorescence assay. By immuno-
electron microscopy using the protein Α-gold method the 16 kDa protein could be clearly 
visualised at the surface of macrogametes and sporozoites, whereas the antigen was not 
detectable in the asexual erythrocytic stages of the parasite. The 16 kDa antigen of P. 
falciparum therefore might have the potential to elicit a dual protective immune response 
against the sporozoite and sexual stage parasites. 
INTRODUCTION 
Malaria, a disease caused by a mosquito-borne protozoan parasite of red 
blood cells, is so widely spread and causes disability so severe that many 
strategies to control it have been devised. One of the strategies is to produce 
sexual stage vaccines that would induce antibodies, which, when ingested in 
a bloodmeal containing sexual stage parasites, would prevent infection of 
mosquitoes and hence transmission (1). Transmission blocking immunity has 
successfully been induced by immunisation with extracellular gametes in 
several species (2-6). In Plasmodium falciparum, the major human malaria 
parasite, three sexual stage-specific antigens (25, 45/48 and 230 kDa) have 
been identified against which monoclonal antibodies block transmission (7-9). 
These antigens represent surface proteins which are expressed during 
different phases of the sexual stage of the parasite. Kaslow et al. (10) have 
recently cloned the gene encoding the 25 kDa protein. The latter protein 
represents a surface protein on zygotes and ookinetes of P. falciparum. 
Cloning and immuno-selection of the other P. falciparum genes involved in 
the induction of transmission blocking immunity has not been achieved so 
far, mainly because the epitopes defined by the transmission blocking 
monoclonal antibodies are dependent on disulphide bonds (8). An alternative 
cloning strategy, namely microsequencing the purified protein followed by 
synthesis of oligonucleotide probes to screen genomic or cDNA libraries, has 
successfully been used for the isolation of the 25 kDa protein encoding Pfs25 
gene (10). 
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We have adopted a novel cloning strategy which does not rely on the 
availability of a peptide sequence to construct hybridisation probes. Instead, 
a subtractive hybridisation technique was used based on the observation that 
de novo synthesis of the antigens involved in transmission blocking immunity 
is most probably restricted to defined stages of gametogenesis and ookinete 
maturation. Screening of a gamete-specific P. falciparum cDNA library for 
the presence of sexual-stage specific encoding sequences by hybridisation 
with radiolabelled single-stranded cDNA probes prepared from sexual and 
asexual stage-specific mRNA resulted in the isolation of a novel gene which 
is specifically expressed in the sexual stages but not in the asexual 
erythrocytic stages of the parasite. Nucleotide sequence analysis showed that 
the gene, named Pfsl6, codes for a protein of 16 kDa which has all the 
characteristics of a surface protein. Immuno-electron microscopy studies 
have clearly demonstrated its presence in the membrane of gametocytes and 
macrogametes. 
Surprisingly, the product of Pfsl6 has also been detected in protein extracts 
of sporozoites while immuno-electron microscopy studies have demonstrated 
its presence on the surface of the sporozoite. 
In view of these aspects the potential of the 16 kDa antigen for the 
development of a transmission blocking and/or a protective sporozoite 
vaccine is discussed. 
MATERIALS AND METHODS 
Isolation of parasites and RNA 
Mature P. falciparum (NF54) gametocytes were produced in a semi-
automated suspension culture system (11). Fourteen days after cultivation, 
infected erythrocytes were harvested by centrifugation for 5 min at 560 χ g. 
Following induction of gametogenesis (12) the macrogametes/zygotes and 
gametocytes were separately recovered by centrifugation through a 
discontinuous Nycodenz (Nyegaard, Oslo) gradient as described by 
Vermeulen et al. (12). After lysis of these cells in 100 mM NaCl, 50 mM 
Tris-HCl, pH 7.2, 50 mM EDTA, 0.2% SDS and 2% Triton-XlOO, the 
RNA was purified by phenol/chloroform extraction and centrifugation 
through a cushion of 5.7 M CsCl in 30 mM NaAc, pH 6.8, and 50 mM 
EDTA (13). 
For the production of sporozoites, fertile gametocytes were produced in 
static tipper cultures (14). Fourteen days after initiation of the cultures, the 
material was harvested, washed, mixed with fresh human red blood cells in 
serum and fed to Anopheles stephensi through parafilm on membrane 
feeders. Mosquitos that had taken a blood meal were separated from the 
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unfed ones and were held at 26 °C and 85% relative humidity until 
dissection. 
Construction and screening of P. falciparum cDNA libraries 
cDNA was synthesized on total gametocyte RNA by oligo(dT)-primed first-
strand synthesis and RNase Η-DNA polymerase I mediated second strand 
synthesis (15). Following homopolymer tailing with dGTP the cDNA was 
annealed into the oligo(dC) tailed Sstl site of plasmid pPLc24511. Vector 
pPLc24511 is a derivate of plasmid pPLc245 (16) in which the 221 bp-long 
SaWRsal restriction fragment has been replaced by the Sstl site containing 
the Sall/Pvuil restriction fragment of M13mpll DNA. After transformation 
into E. coli MC 1061 (17) about 25,000 transformants were obtained. 
The library was screened for the presence of sexual stage encoding 
sequences by differential in situ colony hybridisation with 32P-Iabelled P. 
falciparum cDNAs prepared from RNA isolated from purified 
macrogametes/zygotes, gametocytes or asexual bloodstages, respectively. 
Colonies which hybridised only with macrogamete/zygote and gametocyte 
cDNA probes were purified and rescreened by Northern blot hybridisation to 
verify whether the gene is transcriptionally silent in the asexual blood stages 
of the parasite. 
A P. falciparum lambda-gtll gametocyte cDNA library was constructed as 
described by Wesseling et al. (18). This library was screened by in situ 
plaque hybridisation using a 32P-labelled GB8 cDNA probe. 
Northern blot analysis 
For Northern hybridisation, 3 μg of total cellular RNA (isolated from either 
asexual bloodstages, gametocytes or gametes/zygotes) was loaded on a 1% 
agarose gel containing 2.2 M formaldehyde. The gel was electrophoresed in 
25 mM NaP04 buffer (pH 7.0) and RNA was transferred to nitrocellulose 
(Schleicher & Schuell) in 20 χ SSPE. Hybridisation of the blots was carried 
out at 42°C for 16 hours in 50 mM NaP04 (pH 6.5), 0.8 M NaCl, 50% 
formamide, 1 mM EDTA, 0.1% SDS, 2.5 χ Denhardt's solution, 50 μξ/τηί 
denatured salmon sperm DNA and 500 /xg/ml yeast RNA. The blots were 
washed at high stringency (0.1% SSPE, 0.1% SDS, 65°C). 
Southern blot hybridisation 
Aliquote of genomic P. falciparum DNA (4 μg) and Pfsl6 cDNA were 
digested with the appropriate restriction enzyme. The DNA fragments were 
fractionated by electrophoresis through a 1.5% agarose gel and then 
transferred to nitrocellulose in 10 χ SSC (SSC = 150 mM NaCl, 15 mM 
sodium citrate, pH 7.2). Blots were prehybridised and then hybridised with 
32P-labelIed DNA probes at 60°С for 18 h according to Maniatis et al. (13). 
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After hybridisation they were washed at 25°C with 2 χ SSC and 0.1% SDS, 
and were then autoradiographed. 
The Taql fragments of plasmid pKUN19 (19) were used as molecular weight 
markers. 
Synthesis, purification and conjugation of peptide P31/47 
Peptide P31/47 was synthesized following the stepwise solid-phase strategy 
as described by Barany and Merrifield (21) and subsequently purified by 
reversed-phase high-performance liquid chromatography. 
The synthetic peptide was coupled to bovine serum albumine (BSA) with 
glutaraldehyde according to Geerlings et al (22). 
Construction of pGEX-2T/B-D and pGEX-2T/B-S and isolation of the 
recombinant fusion proteins 
The BamHl-Dral fragment (nucleotide position 183 to 448) and the BamHl-
Sspl fragment (nucleotide position 183 to 593) of Pfsl6 were inserted into 
the BamHl and Smal site of the expression vector pGEX-2T (23). This 
expression vector directs the synthesis of foreign polypeptides in E. coli as 
fusions with the C-terminus of a 26 kDa glutathione S-transferase encoded 
by the parasitic helminth Schistosoma japonicum. The recombinant fusion 
proteins GST/B-D and GST/B-S were isolated by affinity chromatography on 
glutathione beads essentially as described by Smith and Johnson (23). 
Production of polyclonal antisera in rabbits 
New Zealand rabbits were injected subcutaneously with an homogenate of 
200 μg of P31/47 BSA conjugate emulsified in Freund's complete adjuvant, 
and boosted at three-week intervals with P31/47 BSA conjugate in Freund's 
incomplete adjuvant. The rabbits were bled from the main ear vein seven 
days after each boost. Blood was allowed to clot at 4°C overnight and sera 
were stored at -20°С until use. 
The antisera raised against the recombinant fusion proteins were cleared 
from antibodies against E. coli proteins and glutathione-S-transferase 
according the procedures described by Harlow and Lane (24). 
Protein gels and immunoblotting 
Gametes and gametocytes extracts of P. falciparum were prepared by boiling 
1 χ 106 parasites in SDS sample buffer (62.5 mM Tris.HCl, 2% SDS, 10% 
glycerol, 5% 2-mercaptoethanol, 0.003% bromophenol blue, pH 7.2). 
Polyacrylamide gradient gels (10%-20%) containing SDS (0.1%) were made 
and run under denaturing conditions according to Laemmli (25). Proteins 
were transferred to 0.45 μνα nitrocellulose filters as described (26). Prior to 
incubation with a 1:100 dilution of the rabbit antiserum for 1-2 h, the 
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nitrocellulose filters were blocked with 1 % fatfree milkpowder in TBST (50 
mM Tris.HCl, 200 mM NaCl, 5 mM EDTA, 0.05% Tween-20, pH 7.5). 
Vizualization was accomplished with a 1:8000 dilution of alkaline 
phosphatase-goat anti rabbit IgG(H + L) in TBST buffer for 1 hour. After 
extensive washing with TBS the colouring reaction was carried out with 5-
bromo-4-chloro-3-indolyl phosphate (p-toluidine salt, Sigma) and nitroblue-
tetrazolium chloride in 100 mM Tris.HCl (pH 9.5), 100 mM NaCl and 5 
mM MgCl2. The filters were developed until bands appeared, and then 
washed in 20 mM Tris.HCl (pH 8.0) and 5 mM EDTA. 
The enzyme-linked immunosorbent assay (ELISA) 
ELISA plates were coated with 1 /xg/well of either peptide P31/47 or 
recombinant fusion protein in a 50 mM sodium carbonate buffer (pH 9.6) for 
2 h at 37°C. Serum and peroxidase-labeled anti-rabbit IgG were diluted in 
PBS supplemented with 0.2 M NaCl and 0.3% Tween-20. Serum dilutions 
and peroxidase-labeled IgG were incubated for 1 h at room temperature. 
Washings were performed with PBS supplemented with 1 M NaCl and 0.3% 
Tween-20. Peroxidase activity was determined by adding 3,3',5,5'-
tetramethyl-benzidine. The reaction was stopped by the addition of 50 μΐ of 2 
M H2S04. Titers were expressed as the reciprocal of the highest serum 
dilution giving an optical density value > 0.2. 
Immunoelectron microscopy 
P. falciparum (NF54) was cultured in a tipper system and synchronized as 
previously described (27). Blood samples containing gametocytes were taken 
out of culture and immediately fixed. To initiate exflagellation and detect 
gametes, other samples were kept for 10 and 30 minutes at room temperature 
before fixation. Salivary glands were taken from mosquitos, which were 
membrane fed 15 days previously. All samples were fixed for 2 h in 1% 
acrolein/2% paraformaldehyde in 0.1 M phosphate buffer, centrifugated 
(1500 χ g) for 10 minutes and resuspended in 2% (w/v) paraformaldehyde in 
0.1 M phosphate buffer. After one night at 4°C the cells were washed 
extensively in phosphate buffer and the pellet embedded in gelatin (2% w/v). 
After dehydration to ethanol 70% the samples were embedded in L.R. white 
resin, medium grade (London Resin Co. Ltd) and polymerized at 50°C. Thin 
sections were etched for 15 minutes at room temperature in drops of a 
saturated aqueous solution of sodium metaperiodate, rinsed with distilled 
water and preincubated wih 1% bovine serum albumin in 0.1 M phosphate 
buffer. They were subsequently incubated night over in a humid chamber at 
4°C on 50 μϊ drops of the antibody against P31/47 appropriately diluted until 
a concentration of about 25 ¿ig/ml was achieved. The sections were 
thoroughly washed and reacted for 1 h with protein A gold (10 nm) (28). 
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Control sections were incubated with preimmune sera. After final washing 
they were post-fixed for 10 minutes with 2% glutaraldehyde, washed and 
stained with uranylacetate. 
RESULTS 
Isolation and nucleotide sequence of a P. falciparum gene coding for a 
sexual stage-specific protein 
A pPLc24511 gametocyte cDNA library was screened for the presence of 
sexual stage-specific encoding sequences by differential in situ colony 
hybridisation with cDNA prepared from RNA derived from the sexual and 
asexual stages. Ten positive colonies, which strongly hybridised with 
gametocyte and/or macrogamete/zygote cDNA, were purified and rescreened 
by Northern hybridisation analysis to verify whether indeed their P. 
falciparum DNA inserts are only transcribed in the sexual stages of the 
parasite. Two clones, designated GB3 and GB8, contained DNA sequences 
that hybridised with mRNAs of about 1400 bp (Fig. 1). Hybridisation of 
both clones was strong with RNA from gametocytes or 
macrogametes/zygotes, while hybridisation was virtually absent (GB3) or 
weak (GB8) with RNA isolated from the asexual bloodstages. Clone GB3 
contained a cDNA insert of about 1100 bp, which upon sequence analysis 
turned out to be a copy of the Pfs25 gene described by Kaslow et al. (10). 
No differences were found between the cDNA coding sequence of GB3 and 
the genomic sequence reported by this group. A few nucleotide 
replacements, however, were observed within the 3' and 5' untranslated 
regions of the Pfs25 gene (unpublished data). Clone GB8 contained an insert 
of about 800 bp. Nucleotide sequence analysis showed that the GB8 cDNA 
was incomplete since it lacked part of the 5' coding region. To establish the 
complete nucleotide sequence a lambda-gtll gametocyte cDNA library was 
screened with the GB8 clone for the presence of larger DNA inserts. One of 
the positive cDNA clones (GB8c), obtained after plaque hybridisation, 
contained an insert of 1100 bp and was selected for further sequence 
analysis. The nucleotide sequence of the cDNA insert (Fig. 2) revealed a 5' 
untranslated region of 70 bp, an open reading frame of 471 bp and a 3' 
untranslated region of 94 bp. The open reading frame codes for a 157 amino 
acids-long polypeptide with a molecular weight of 16,607. The A+T content 
of the coding sequence (64%) is substantially lower than that of the 5' (87%) 
and 3' (99%) flanking sequences. Furthermore, the coding region shows a 
preference for A over Τ residues in the mRNA strand whereas the A+T 
content of the three codon positions increases from the first to the third 
position. These features are characteristic for P. falciparum genes (29). 
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Fig. 1. Northern blot analysis of 
P. falciparum RNA. Total RNA 
from gametes/zygotes (lanes Al 
and Bl), gametocytes (lanes A2 
and B2) and asexual blood stages 
(lane A3 and B3) was 
electrophoresed and blotted onto 
nitrocellulose. The blots were 
hybridised with probes of high 
specific radioactivity prepared by 
in vitro transcription of the GB3 
(blot A) and GB8 (blot B) 
inserted fragments which had 
previously been ligated in the 
poly linker of pGEMblue. 
To find out whether the genomic copy of the coding sequence of this cDNA 
is interrupted by introns, hybridisation data from Ssp\-c\it GB8c cDNA were 
compared with those of Sspl-cut genomic P. falciparum DNA. The Ssp\ 
cDNA fragment was chosen since it ranges from nucleotide position 76 to 
590 and contains, except for the first two amino acid residues, the entire 
coding sequence (Fig. 2). The hybridisation data, depicted in Fig. 3, indicate 
that the gene, further denoted as the Pfsl6 gene, is not interrupted by introns 
and hence contains a reading frame that codes for a polypeptide of 157 
amino acids. 
A two-dimensional representation of secondary structure predictions for the 
Pfsl6 protein using the UWGCG program (30) is shown in Fig. 4. The N-
terminus contains a stretch of 20 hydrophobic amino acid residues preceded 
by two basic residues and followed by acidic residues. These structural 
features suggest that the N-terminal sequence functions as a signal peptide. 
In addition to this, the Pfsl6 protein contains a second hydrophobic region, 
specified by amino acid positions 104-126 which might function as a 
membrane anchor sequence. This anchor then is followed by a putative short 
cytoplasmic domain which is very rich in the polar amino-acids aspartate, 
glutamate and lysine. These characteristics strongly suggest that after its 
synthesis the Pfsl6 protein is inserted into the cellular membrane in such a 
way that the C-terminal domain is located at the cytoplasmic face. 
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17 ttta ttttttattt ttttttctttt gccatttttc tatttatact ttcttcaac 
1 met asn lie arg lys phe lie pro ser leu ala leu met leu Ile 
71 ATG AAT ATT CGA AAG TTC ATA CCA TCT TTA GCT TTA ATG CTT ATA 
16 phe phe ala phe ala asn leu vai leu ser asp ala asn asp lys 
116 TTC TTC GCT TTT GCA AAC CTG GTA TTA TCA GAT GCA AAT GAC AAA 
31 ala lys lys pro ala gly lys gly ser pro ser thr leu gin thr 
161 GCA AAA AAG CCC GCT GGA AAA GGA TCC CCT TCA ACT TTG CAA ACC 
BamHI < 
46 pro gly ser ser ser gly ala ser leu hls ala val gly pro asn 
206 CCA GGA AGT TCT TCA GGT GCC TCT CTT CAT GCT GTT GGA CCT AAT 
61 gin gly gly leu ser gin gly leu ser gly lys asp ser ala asp 
251 CAA GGT GGA СТА TCT CAA GGT CTT TCT GGA AAA GAT TCT GCT GAC 
76 lys met pro leu glu thr gin leu ala Ile glu glu lie lys ser 
296 AAA ATG CCT TTA GAA ACT CAG СТА GCT ATA GAA GAA АТС AAG AGC 
91 leu ser asn met leu asp lys lys thr thr val asn arg asn leu 
341 TTA TCC AAT ATG TTA GAT AAA AAA ACG АСА GTT AAC AGA AAC TTA 
106 lie lie ser thr ala val thr asn met lie met leu lie lie leu 
386 АТС ATA AGT ACT GCT GTC АСА AAT ATG АТС ATG TTG АТС ATA TTA 
121 ser gly lie val gly phe lys val lys lys thr lys asn ala asp 
431 TCT GGT ATA GTT GGA TTT AAA GTT AAA AAA ACG AAG AAC GCA GAT 
. Dra I . 
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151 g l y asp g l u g l y asp asp s e r * * * 
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570 t a t t t a t t t a t t t a t t t a a a t a t t t a t a t a t a t a t a t a t a t t a t a t a t a t aata 
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Fig. 2. Nucleotide sequence of the Pfsl6 coding region and flanking regions. The 
deduced amino acid sequence is indicated above the nucleotide sequence. The amino acid 
sequence of the synthetic peptide P31/47 is boxed. The nucleotide sequence was 
established by the dideoxy chain termination method (20) using M13mpl0/mpll as 
sequencing vectors. 
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Fig. 3. Restriction and hybridisation 
analysis of P. falciparum DNA. The 
Pfsl6 cDNA clone GB8c (lane 1) and P. 
falciparum genomic DNA (lane 2) were 
digested with Sspl, electrophoresed, 
blotted and hybridised with a 3 2P labelled 
Sspl fragment from Pfsl6 cDNA. The 
positions of migration of the Taql 
fragments of plasmid pKUN19 used as 
molecular weight markers are indicated. 
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Fig. 4. Two-dimensional representation of secondary structure predictions according to 
Chou-Fasman for the Pfsl6 protein using the GCG Sequence Analysis software program 
(University of Wisconsin). 
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In contrast to the Pfs25 protein which is extremely rich in disulphide bonds 
(10), the Pfsl6 protein sequence does not contain cysteine. It also does not 
contain tryptophan and tyrosyl residues nor does it have potential 
glycosylation sites (Asn-X-Ser/Thr) for N-linked sugars. 
Identification of the protein encoded by the Pfsl6 gene 
To identify the protein encoded by the Pfsl6 sequence, rabbit antisera were 
raised against a synthetic peptide (P31/47) consisting of the amino acid 
sequence from position 31 to 47 of the Pfsl6 antigen (cf. Fig. 3). This 
protein segment was chosen on the basis of its potential antigenic properties. 
Rabbit antisera were also raised against the recombinant fusion proteins 
GST/B-D (glutathione S-transferase linked to a Pfsl6 polypeptide consisting 
of amino acid residues 39-126) and GST/B-S (glutathione S-transferase/Pfsl6 
polypeptide 39-157) as described under Materials & Methods. With each of 
these antibodies a 16 kDa antigen was detected by Western blot analysis of 
macrogamete/zygote and gametocyte proteins (Fig. 5). Interestingly, the 
same antigen was also detected in protein extracts of sporozoites. As a 
control, the pre-immune sera did not show any reaction on the Western 
blots. 
No 16 kDa antigen could be discerned when Western blot analysis was 
carried out with proteins from the asexual bloodstages indicating that the 16 
kDa protein is a protein component not only of the sexual stages but also of 
sporozoites. 
Localisation of the 16 kDa antigen 
Rabbit antisera raised against P31/47, GST/B-D and GST/B-S were used to 
localise the 16 kDa antigen within the gametocyte, macrogamete and 
sporozoites by the indirect immunofluorescence antibody test (IFA). These 
studies showed that the 16 kDa antigen is located mainly on the membrane 
of these parasitic forms (unpublished data). 
By immunoelectron microscopy it could be demonstrated that the 16 kDa 
antigen is located on the membrane of the intracellular gametocytes and 
possibly on the parasitophorous vacuole membrane (Fig. 6A), on outer 
membrane of extracellular macrogametes (Fig. 6B) and on the surface of 
sporozoites (Fig. 6D). Asexual bloodstage parasites (Fig. 6C) and mature 
exoerythrocytic forms did not react with these sera indicating the absence of 
this 16 kDa protein. The pre-immune rabbit serum used as a control was 
negative. Similarly, P. vivax sporozoites did not react with these P. 
falciparum anti sera. 
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Fig. 5. (a) Western blot analysis of proteins extracts prepared from total asexual 
bloodstages (A), macrogametes/zygotes (B) and gametocytes (C), using rabbit preserum 
(Al, Bl and CI) and rabbit antiserum raised against peptide P31/47 (A2, B2 and C2). 
Equal amounts of parasites (1 χ IO6) were applied to each lane, (b) Western blot analysis 
of total gamete (1) and sporozoite (2) proteins using rabbit antiserum raised against 
GST/B-D. (c) Western blot analysis of total macrogamete proteins using (1) rabbit 
antiserum against peptide P31/47, (2) polyvalent rabbit serum K1808 raised against 
macrogametes and gametocytes and (3) serum Hstell obtained from an adult living in a 
highly endemic region. 
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Fig. 6. Localisation of the 16 kDa antigen in gametocytes, gametes and sporozoites of P. 
falciparum by immuno-electron microscopy. (A) Intra-erythrocytic gametocyte with gold 
label on surface membranes and possibly on parasitophorous vacuole membrane. (B) 
Extracellular macrogamete showing labelling of outer surface membranes. (C) Asexual 
schizont reacting negative with the anti 16 kDa serum. (D) Sporozoites in mosquito 
salivary gland demonstrate the goldlabel at the surface. Bar = 0.5 μίτι. 
DISCUSSION 
Here we report the isolation of a novel gene of P. falciparum, Pfsl6, which 
codes for an integral membrane protein and which is predominantly 
transcribed during the sexual stages of the parasite. From its nucleotide 
sequence it is deduced that the Pfsl6 gene encodes a protein of 157 amino 
acids. The amino acid sequence of the 16 kDa protein contains a putative 
signal peptide at the N-terminus, a short hydrophobic membrane anchor in 
the second half of the protein molecule and a cytoplasmic (hydrophilic) 
region at the C-terminus, i.e. structural features which make it very likely 
that the 16kDa protein is a membrane protein. 
44 
It is remarkable that both genes currently known to be expressed 
predominantly in the sexual stages of the parasite, namely the Pfs25 (10) and 
the Pfsl6 gene reported here are non-interrupted genes. They do not carry 
polymorphic repetitive regions which are commonly found in many other P. 
falciparum proteins (31,32). Variation in these repeats is a potential problem 
for the immunoprophylaxis of malaria (33). Under selective pressure of the 
immune system populations of parasites can rapidly change the protein 
repeats and the effectiveness of repeat-containing vaccines will be limited. 
Phenotypic heterogeneity in the repetitive portion of the human P. vivax 
circumsporozoite (CS) protein, a major target of candidate vaccines, has 
been found (33). This heterogeneity implies that a P. vivax vaccine based on 
the CS protein repeat of one isolate will not universally be protective. Taken 
into consideration that the 16 kDa protein is located in the membrane of 
extracellular macrogametes and sporozoites as well makes this protein an 
attractive candidate both for the assessment of a transmission blocking and a 
sporozoite vaccine. 
Western blot analysis has shown that the Pfsl6 gene is expressed in the 
sexual stages of the parasite and in sporozoites but not in the asexual stages 
or in P. vivax sporozoites. A specific 16 kDa antigen was detected among 
the gametocyte, macrogamete/zygote and sporozoite proteins, using 
antibodies raised against a synthetic peptide (P31/47) of the Pfsl6 protein 
and against the 16 kDa protein containing recombinant fusion proteins 
GST/B-D and GST/B-S. These antibodies also detected the 16 kDa antigen 
on glutaraldehyde fixed gametes and gametocytes in a standard immuno-
fluorescence assay. The suggestion that the Pfsl6 protein is an integral 
membrane protein of the sexual and asexual sporozoite stages is confirmed 
by immuno-electron microscopy. 
At present three sexual-stage specific antigens, i.e. the 25 kDa, the 45/48 
kDa doublet and the 230 kDa components, are considered as prime 
candidates for a transmission-blocking vaccine whereas the CS protein is 
currently the best candidate for a sporozoite vaccine. The 25 kDa protein is 
a very attractive candidate since the protein is highly immunogenic, and its 
primary sequence is conserved among world-wide spread P. falciparum 
isolates (34). However the presence of EGF-like domains in the 25 kDa 
antigen might become a problem, because shared sequences between host 
and pathogen in other diseases have been implicated in severe autoimmune 
complications. Conclusions on the 45/48 kDa and the 230 kDa candidates 
cannot be drawn yet since structural and immunological information of these 
antigens are still lacking. Computer search analysis at the DNA as well as 
the protein level have indicated that the new candidate described in this 
report, i.e. the Pfsl6 gene and its derived protein sequence, has no 
significant similarity with any other DNA or protein sequence known so far. 
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Preliminary investigations have also indicated that the Pfsl6 gene product is 
species-specific; antibodies against the P. falciparum 16 kDa protein did not 
react with P. berghei gametocyte proteins on Western blots. Furthermore, 
polymerase chain reaction studies on P. berghei, P. yoelii and P. vivax DNA 
did not reveal the presence of DNA sequences in these species similar to the 
Pfsl6 gene sequence (unpublished data). Although the precise biological 
function of the 16kDa protein has yet to be established, the features of Pfsl6 
suggest that it might be a candidate for a transmission blocking/sporozoite 
vaccine. Polyvalent rabbit sera raised against gametes and gametocytes, and 
which have high transmission blocking activity, clearly recognise the 16 kDa 
protein on Western blots. A similar immuno-positive reaction on Western 
blots is observed with sera from adults living in highly endemic regions (cf. 
Fig. 5b). Experiments to determine whether peptide P31/47 or other parts of 
the protein induce transmission blocking or inhibit sporozoite invasion are 
currently under investigation. Preliminary studies have already indicated the 
involvement of the Pfsl6 gene product as a sporozoite binding factor in 
hepatocyte invasion. 
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CHAPTER 3 
Gene Pfsl6 of 
Plasmodium falciparum is expressed both in sexual stages and sporozoites 
Moelans, I.I.M.D., de Wilde, P., van Gemert, G.J.A., Eling, W.M.C., 
Schoenmakers, J.G.G. and Konings, R.N.H. 
Parasitology, submitted for publication 

ABSTRACT 
By one-dimensional and two-dimensional Western blot analysis using Pfsl6 specific 
monoclonal antibodies it could be demonstrated that the 16 kDa proteins previously found 
to be present in gametocytes and sporozoites (1) are identical. RT-PCR analysis of 
affinity-captured RNA revealed the presence of Pfsl6-specific mRNA in both gametocytes 
and sporozoites. By Northern blot analysis it could be demonstrated that the Pfsl6 gene is 
expressed in sporozoites via two mRNA species with sizes of 1.4 and 3 kb respectively, 
while in sexual stages the gene is only expressed via one mRNA species with a size 
identical to that of the smallest found in sporozoites. The molecular mechanism(s) 
underlying this differential expression is (are) currently under investigation. 
INTRODUCTION 
The human malaria parasite Plasmodium falciparum (P. falciparum) follows 
a very complex life cycle during which surface antigens are expressed 
developmental stage specifically. Until recently generally it has been believed 
that the parasite is able to escape from a protective immune response via 
transformation from one stage of its life cycle to the next (2). This property 
has very important implications for vaccine development, because an 
effective vaccine most likely has to be devised to generate a protective 
response against two or more developmental stages (3-5). Thus far, only a 
few ('protective') antigens have been identified which indeed are expressed 
at various developmental stages of the parasite. Notable examples of antigens 
expressed at two or more developmental stages are RESA, CS protein and 
GLURP (reviewed in ref. 6). It is clear that 'protective' antigens expressed 
at various developmental stages of the parasite are prime candidates for 
vaccine development. 
By using different experimental approaches, such as immunoblotting, 
immunofluorescence and immunoelectron microscopy, antigens reacting with 
polyclonal antibodies specific for Pfsl6, a potential candidate antigen for the 
development of a malaria vaccine, were found to be present in cells of 
sexual stages and sporozoites (1,7). 
To prove that indeed we were dealing with one and the same antigen in 
gametocytes and sporozoites, one- and two-dimensional Western blot analysis 
was performed using Pfsl6 specific monoclonal antibodies. In addition it was 
studied whether both in gametocytes and sporozoites identical Pfsl6 specific 
mRNAs were present. 
51 
MATERIALS AND METHODS 
Monoclonal antibodies 
Two Pfsl6 specific mouse monoclonal antibodies were used; 32F717 and 
2G7. 32F717 was obtained from Dr. Pieter Beckers (Department of Medical 
Parasitology, University of Nijmegen, The Netherlands) and was affinity 
purified from ascites fluid. This monoclonal antibody was diluted to 1 mg/ml 
in phosphate-buffered saline (PBS) and reacts with the central domain of the 
Pfsl6 antigen (data not shown). 2G7 (ascites fluid) was a generous gift from 
Dr. Richard Carter (Department of Genetics, University of Edinburgh) and 
reacts with the C-terminal domain of the Pfsl6 antigen (8). 
Purification of gametocytes, gametes and sporozoites 
Gametocytes, gametes/zygotes and sporozoites were purified as described 
(1). Washed, pelleted parasite preparations were stored frozen at -70°C. 
One-dimensional and two-dimensional Western blot analysis 
For one-dimensional SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis 3.106 parasites were solubilised in sample buffer (62.5 mM Tris-
HC1, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.003% 
bromophenolblue, pH 7.2). Proteins were separated by electrophoresis on a 
12.5% Polyacrylamide gel under denaturing conditions (9). 
For two-dimensional gel electrophoresis 1.106 gametocytes and/or 1.106 
sporozoites were solubilised in isoelectric focusing (IEF) sample buffer (7 M 
urea, 2% NP-40, 1% ampholines, pH 5-8). Proteins were first fractionated 
according to their isoelectric point. IEF was carried out in horizontal 
Polyacrylamide (5%) slab gels containing 7 M urea and 2% NP40 with a pH 
gradient from 5 to 8 using the LKB Multiphor equipment as described (10). 
The 1.2 mm thin Polyacrylamide gels were casted on glass plates using as a 
support a GelBond PAG polyester film (FMC Corporation, USA) according 
to the manufacturer's instructions. pH gradients were measured by soaking 
gel slices of 0.5 cm overnight and at room temperature in 3 ml of 
demineralised water. After IEF, the strips containing the proteins were cut 
from the gel with a razor blade and soaked for 5 minutes in SDS-PAGE 
sample buffer (62.5 mM Tris-HCl, 2% SDS, 10% glycerol, 5% 2-
mercaptoethanol, 0.003% bromophenolblue, pH 7.2) and then loaded onto a 
12.5% Polyacrylamide gel. Proteins were separated by electrophoresis under 
denaturing conditions (9). After electrophoresis they were transferred 
electrophoretically to 0.45 μπι nitrocellulose filters (11). Blots were blocked 
with 3% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), 
supplemented with 0.1 % Tween-20 (PBST), for 1 hr at room temperature. 
After extensive washing with PBST, the blots were incubated for 1 hr at 
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room temperature with one of the two monoclonal antibodies after dilution 
1/100 in PBST. Following three washes in PBST, alkaline phosphatase-rabbit 
anti-mouse IgG was added and incubation was continued for 1 hr at room 
temperature. After extensive washing of the blots with PBS, they were 
incubated in 5-bromo-4-chloro-3-indolyl phosphate and nitroblue-tetrazolium 
chloride in order to visualise the immune complexes. 
Northern blot analysis 
For Northern blot analysis 10 /xg of total cellular RNA, prepared from either 
asexual bloodstages, gametocytes, gametes/zygotes or sporozoites, was 
separated on a denaturing formaldehyde agarose (1%) gel and subsequently 
transferred to a nitrocellulose membrane (1). Subsequently, the membrane 
was incubated in a solution containing the Sspl fragment of gene Pfsl6 
radiolabelled with (a-32P)dATP as described (1). After hybridisation, the 
membrane filter was washed at high stringency (0.1% SSC; 0.1% SDS, 
65 °C) and subsequently autoradiographed. 
RT-PCR analysis of affinity-captured RNA 
Stage-specific poly(A)+ RNA was isolated from gametocytes and sporozoites 
by affinity chromatography using the Dynabeads oIigo(dT)25 mRNA 
purification kit (Dynal As, Oslo). To this end 1.107 frozen parasites were 
solubilised in 100 μί of lysis/binding buffer (100 mM Tris-HCl, 500 mM 
LiCl, lOmM EDTA, 1% SDS, 5 mM dithiothreitol, pH 8.0). Then the lysate 
was centrifugated for 30 seconds in an Eppendorf centrifuge, the supernatant 
was saved and transferred to a tube containing 0.15 mg of Dynabeads 
oligo(dT)25, suspended in 100 μί of lysis/binding buffer. After annealing for 
3-5 minutes on ice followed by several washings of the beads with 0.1 ml of 
washing buffer (10 mM Tris-HCl, 0.15 M LiCI, 1 mM EDTA, 0.1% SDS, 
pH 7.5), mRNA was eluted by incubation of the beads for 2 min at 65°С 
with 10 μί of elution buffer (2 mM EDTA, pH 7.5). 
For the detection of Pfsl6 specific mRNA with the aid of the polymerase 
chain reaction the Perkin-Elmer Cetus Gene Amp Thermostable rTth Reverse 
Transcriptase RNA PCR (RT-PCR) kit was used. After elution 1 μί of the 
mRNA was transcribed into cDNA using oligo(dT)16 as a primer. 
Subsequently the cDNA was amplified with the aid of the Pfsl6 specific 
primers (sense: 5'-GGAATTCATTTAAGAATCATCTCCTTCGTCTCC-3' 
and antisense: 5'-CCCCGGGTCTTCAACATGAGAATATTCGAA-
AGTTC3') (12). All reactions were performed according to the instructions 
of the manufacturers. As a control for the absence of genomic DNA in the 
mRNA preparation, RT-PCR reactions were also performed in the absence 
of the oligo(dT)16 primer. After amplification one tenth of the reaction 
mixtures was applied onto a 1% agarose gel according to standard 
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procedures (13). After electrophoresis, amplification products were 
transferred to a nitrocellulose filter and then hybridised with a 32P-Iabelled 
Pfsl6 specific cDNA probe as described (1). 
RESULTS 
Immunoblot analysis 
In contrast to normal mice sera both the monoclonal antibody 2G7, which 
recognises an epitope in the C-terminal region of Pfsl6 (8), and 32F717, 
which recognises an epitope in the central domain of the Pfsl6 antigen, 
reacts specifically with a 16 kDa antigen present on blots prepared from 
proteins purified from both sporozoites and gametocytes (Fig. 1). 
Fig. 1. Immunoblot analysis of 
protein extracts prepared from 
gametocytes and sporozoites. 
SDS lysates of gametocytes 
(lanes 1) and sporozoites (lanes 
2) of P. falciparum (isolate 
NF54) were subjected to SDS-
PAGE under reducing conditions 
and transferred to nitrocellulose 
membranes. The presence of the 
Pfsl6 antigen was visualised via 
incubation of the blots with the 
monoclonal antibodies 32F717 
(A) or 2G7 (B). 
Similar results were obtained if gametocyte and/or sporozoite specific 
proteins were analysed by two-dimensional immunoblot analysis. In each 
case a single protein with an identical electrophoretic mobility and of the 
same isoelectric point was detected (Fig. 2). 
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Fig. 2. Two-dimensional immunoblot analysis of protein extracts prepared from 
gametocytes (A), gametocytes+sporozoites (B) and sporozoites (C). Proteins were 
separated by two-dimensional gel electrophoresis and then transferred to nitrocellulose 
membranes as decribed in the Materials and Methods section. The presence of the Pfsl6 
antigen was visualised via incubation of the blots with the monoclonal antibody 32F717. 
The positions of migration of molecular weights markers are indicated on the right-hand 
side of the blots, while the pH range is indicated at the top of the blots. 
Detection of Pfsló-specifìc mRNA in sporozoites and sexual stages 
To study whether both in sporozoites and sexual stages Pfsl6 specific mRNA 
is present total cellular RNA was fractionated under denaturing conditions on 
agarose gels and blotted onto nitrocellulose paper. Subsequently, Pfsl6 
specific RNA was visualised by hybridisation with a Pfsl6 specific cDNA 
probe. As shown in Fig. 3 with RNA prepared from gametocytes and 
gametes/zygotes (lanes 3 and 4) strong hybridisation with an mRNA of about 
1.4 kb was found. Interestingly, after hybridisation of blots prepared from 
sporozoite RNA two very weakly hybridising RNA species were found (Fig. 
3, lane 1); in both situations identical amounts of RNA were loaded onto the 
gel. One of these mRNA species had a size similar to that detected in 
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gametocytes/gametes while the other was about twice as long. The low 
amount of Pfsl6 mRNA detected in the asexual bloodstages (Fig. 3, lane 2) 
is most probably the result of the unavoidable presence of small amounts of 
gametocytes in the asexual bloodstage preparation (T. Lensen, personal 
communication). This conclusion is additionally supported by the results of 
studies published previously (1). 
Fig. 3. Northern blot analysis of P. 
falciparum RNA. Total RNA from 
sporozoites (lanel), asexual 
bloodstages (lane 2), gametocytes 
(lane 3) and gametes/zygotes (lane 4) 
of P. falciparum was fractionated on 
a denaturing formaldehyde agarose 
gel (1%) and blotted onto 
nitrocellulose. The blot was 
hybridised with a 32P-labelled Sspl 
fragment of Pfsl6. The positions of 
migration of RNA molecular weight 
markers are indicated in kb at the left 
side. 
To further confirm that the RNA detected in sporozoites was indeed Pfsl6 
specific mRNA, poly (A)+ RNA was isolated from gametocytes and 
sporozoites by affinity chromatography, reverse transcribed with oligo(dT)16 
primer and subsequently amplified by PCR using two nested Pfsl6 specific 
primers. After amplification, one-tenth of each cDNA mixture was 
fractionated on a 1 % agarose gel and then blotted onto a nitrocellulose filter. 
Then the filter was incubated with a 32P-labelled Pfsl6 specific probe. As 
shown in Fig. 4 (lanes 2 and 3), Pfsl6-specific DNA fragments of uniform 
sizes (470 bp) were formed after RT-PCR amplification of both sporozoite 
and gametocyte poly (A)+ RNA but no (Pfsl6 specific) products were 
detected when the oligo(dT)16 primer was omitted from the reverse 
transcription reaction mixture. The sizes of fragments formed are consistent 
with the distance of the Pfsl6 specific primers in the cDNA sequence 
published previously (1). 
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Fig. 4. Autoradiograph of a Southern 
blot obtained after fractionation of 
RT-PCR products on a 1% agarose 
gel. In lane 1 the products of a 
reaction mixture incubated without 
added RNA are loaded. RT-PCR 
products of gametocyte poly(A)+ 
RNA and sporozoite poly(A)+ RNA 
are loaded in lanes 2 and 3, 
respectively. In lanes 4 and 5 the RT-
PCR products of gametocyte 
poly(A)+ RNA (lane 4) and 
sporozoite poly (A)+ RNA (lane 5) 
incubated without oligo(dT)16 primer 
in the reverse transcription reaction 
were loaded onto the gel. 
DISCUSSION 
The parasite P. falciparum grows and differentiates in a highly regulated 
manner both in its human and mosquito hosts. At several points in its 
complex life cycle, the parasite must express the appropriate genetic 
information in order to be able to switch from one stage to another (14,15). 
It is clear that intricate gene regulatory circuits must be operative. Currently, 
fairly nothing about these regulatory mechanisms is known. In recent years, 
however, there has been great progress in characterising antigens of the 
different life cycle stages of P. falciparum. It was observed that many 
malaria proteins, particularly surface antigens, are expressed stage-
specifically (2). For a few antigens, however, e.g. CS protein, RESA and 
GLURP, firm evidence has been collected that they are expressed at two or 
more developmental stages (reviewed in ref. 6). The data presented in the 
present study provide evidence that this is also the case for the Pfsl6 antigen 
which is expressed both in sexual stages and sporozoites. Using monoclonal 
antibodies 2G7 and 32F717 a reaction with a single protein of molecular 
weight 16 kDa was observed by one-dimensional Western blot analysis of 
protein extracts prepared from gametocytes and sporozoites. The results of 
two-dimensional Western blot analysis highly support the conclusion that 
these 16 kDa proteins are products of one and the same gene. Our previous 
studies (1) have demonstrated that in gametocytes and gametes/zygotes the 
Pfsl6 gene is expressed via a single RNA species that is 1.4 kb long. The 
data derived from Northern blot analysis and RT-PCR as presented in this 
paper confirm these observations. They furthermore demonstrate that in 
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sporozoites two different, less abundant, Pfsl6 specific mRNA species are 
made of which one has a size identical to that found in sexual stages. The 
other is about twice as long. The latter observations strongly indicate that in 
sporozoites either the Pfsl6 gene is transcribed from two different 
promoters-one that is active during gametocytogenesis while the other most 
likely is activated during the onset of sporogony-or a differential 
polyadenylation process is used. The observation that a gene simultaneously 
is expressed from two different promoters is not unique. Heterogeneity of 
transcription initiation has previously been demonstrated for the P. 
falciparum PMMSA gene (16), the P. knowlesi CSP gene (17) and the P. 
yoelii Py230 gene (18). Very recently, stage-specific transcription of the 
Pfmdrl gene during the erythrocytic cycle of P. falciparum has been 
reported (19,20). Concerning the differential polyadenylation, recently it was 
demonstrated that the transcript encoding the CS protein of Plasmodium 
berghei utilises heterogeneous polyadenylation sites (21). It might be argued 
that the occurrence of two different Pfsl6 specific mRNA species is due to a 
differential splicing. Several genes, like the rat τ-fibrinogen gene and the c-
Ki-raj2 gene, are known to use alternative splicing to generate diversity in 
their mRNA products (22). The fact however that both in the 5' and 3' non-
translated regions no consensus splice sites have been found (K. Dechering, 
personal communication) disfavour this alternative. 
The functional meaning of the existence of the two weakly expressed Pfsl6 
specific transcripts in sporozoites is still unknown. It implies that 
transcription of Pfsl6 is regulated in a stage specific manner, the abundance 
of transcript(s) varying during parasite development, and certain initiation 
and/or polyadenylation sites being used preferentially at particular stages. An 
analysis of the DNA region, including the promoter, located upstream of the 
Pfsl6 gene and a study of the polyadenylation sites used by the Pfsl6 
transcript is expected to deliver further insight into the mechanisms that 
underly the differential expression of the Pfsl6 gene. These studies are 
currently in progress. 
The results from this study as well as the findings of previous experiments 
(1) are at variance with the observations of Baker et al. (7) who did not 
detect the gene encoded polypeptide in sporozoites, although they were able 
to identify Pfsl6 specific transcript(s) in sporozoites. We do not know what 
factors may account for their inability to detect the Pfsl6 antigen in 
sporozoites, but the present study clearly demonstrates the presence of the 
Pfsl6 antigen in both gametocytes and sporozoites and indicates that 
transcription of the Pfsl6 gene is regulated in a stage specific manner. 
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CHAPTER 4A 
Minimal variation in Pfsl6, a novel protein located 
in the membrane of gametes and sporozoites 
of Plasmodium falciparum 
Moelans, I.I.M.D., Klaassen, C.H.W., Kaslow, D.C. 
Konings, R.N.H. and Schoenmakers, J.G.G. 
Molecular and Biochemical Parasitology 46 (1991), 311-314 

Recently, we reported the characterisation of Pfsl6, a novel sporozoite and 
sexual stage specific surface antigen of Plasmodium falciparum (1). Although 
the precise biological function of this 16 kDa protein is not yet known, its 
biochemical and immunological properties suggest that it is a potential 
candidate for the development of a transmission blocking and/or anti-
sporozoite vaccine. To assess the significance of Pfsl6 as a candidate for the 
development of such a multi-stage vaccine, we have analysed the amino acid 
sequence diversity of Pfsl6 in P. falciparum isolates collected from eight 
different geographic areas, namely South America (Brazil: 7G8 (2)), West 
Africa (Liberia: LE5, LF4 (3)); Ghana, GH1), Central America (Honduras: 
HB3 (4)), Southeast Asia (Malaysia: CAMP (5); Indochina: Dd2 (6)) and 
NF54 (7) collected from an indeterminate origin. 
The amino acid sequence of Pfsl6 in each isolate was deduced from the 
nucleotide sequence of the amplified gene. For PCR-amplification of the 
intronless Pfsl6 gene (coding region of 471 basepairs) one pair of primers (a 
and b) was used (Fig. 1). To eliminate sequencing errors caused by Taq 
polymerase misincorporation the nucleotide sequence of each isolate was 
determined directly (8) from amplified material using three sequencing 
primers (Fig. 1). The analysis revealed that the Pfsl6 coding sequence in the 
isolates 7G8, LF4, LE5, HB3 and CAMP is completely identical to that of 
isolate NF54, the sequence of which has been reported previously (1; see 
also 9). 
ATG [ 100bp -| TAA 
с d e b 
Fig 1. Schematic representation of the Pfsl6 gene. The arrows indicate the 
positions and 5'-3' directions of the amplification primers 
(a: 5'-GGAATTCATTTAAGAATCATCTCCTTCGTCTCC-3* and 
b: 5'-CCCCGGGTCTTCAACATGAGAATATTCGAAAGTTC-3') and sequencing 
primers (c: 5'-TCTGGAAAAGATTCTGCTGAC-3', d: 5'-GTTTCTGTTAACTGTCG-3' 
and e: 5'-CGTTTTTTTAACTTTGAATCCAAC-3')· 
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In the Pfsl6 gene sequence of the drug-resistant and poorly transmissible 
Dd2 isolate (6), an Α-T transversion at nucleotide position 253 and a G-A 
transition at nucleotide position 269 were found, thus resulting in a 
conservative substitution of leucine for isoleucine at amino acid position 85 
and a nonconservative substitution of asparagine for serine at position 90, 
respectively (Fig. 2). As a consequence of this substitution, at position 90 a 
potential N-glycosylation site (Asn-X-Ser/Thr) was generated. Similar to 
isolate Dd2, in the Ghana isolate GH1 at amino acid position 85 the 
conservative Ile-Leu substitution was found. Furthermore, in the GH1 gene 
between nucleotides 417 and 418 an insertion of the hexanucleotide 
GAT.AAA (Asp-Lys) was noted. This insertion is most probably caused by 
a slipped mispairing during the replication of the tandem repeat 
GAT. A AG. G AT. A AG (nucleotide positions 418 through 429) located 
immediately distal of it (Fig. 2; cf. (11)), followed by a G to A transition of 
the sixth nucleotide. 
85 90 
leu ala ile glu glu ile lys ser leu ser 
247 276 
NF54 СТА GCT ATA GAA GAA АТС AAG AGC TTA TCC 
Dd2 Τ ... .Α. 
leu asn 
GHl T.. 
leu 
140 145 
asp asp lys gly asp lys asp lys asp lys 
406 435 
NF 5 4 GAT GAT AAA GGA GAT AAG GAT AAG GAC AAG 
GHl 
GAT AAA 
asp lys 
Fig. 2. Nucleotide sequence differences among the Pfsl6 genes of eight different isolates 
of Plasmodium falciparum. Presented are the nucleotide and amino acid sequences of 
Pfsl6 regions of isolate NF54 that deviate from those of two other isolates. Numerals 
indicate the nucleotide or amino acid positions in the established sequence (1). Identical 
sequences were found in the isolates NF54, 7G8, LE5, LF4, HB3 and CAMP. The 
sequence differences found in isolates Dd2 and GHl are indicated. 
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From the data collected it can be concluded that the amino acid sequence 
diversity of the Pfsl6 antigen is almost negligible. The observation that not 
each of the amino acid substitutions in isolates Dd2 and GH1 is completely 
random is remarkable. Whether the 'preferred' substitution at amino acid 
position 85 is a reflection of the functional organisation of the Pfsl6 antigen 
deserves further investigation. 
Because the nucleotide sequences of Pfsl6 were derived from amplified 
DNA from asexual parasites that have been cultured in vitro for many 
generations, and because the Pfsl6 gene is not expressed in these asexual 
(blood) stages (1), the nucleotide sequence of the gene that we have analysed 
has not had genetic pressure to produce a functional protein for growth and 
survival. Despite the absence of this pressure we observed only in two 
isolates a few amino acid substitutions. These data, together with the 
observation that antibodies to Pfsl6 frequently could be detected in sera 
derived from malaria patients in endemic areas (unpublished results), not 
only suggest that P. falciparum must possess an extremely efficient DNA 
replication and/or DNA mismatch repair system but also that a significant 
alteration of the amino acid sequence of the Pfsl6 antigen is probably 
deleterious to the parasite. Minimal antigenic diversity has also been 
observed by Kaslow et al. (10) for Pfs25, the sexual stage specific (zygote 
and ookinete) surface antigen of P. falciparum. In how far a severe 
restriction of antigenic diversity is a unique property of the sexual stage 
specific antigens cannot be answered yet. 
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CHAPTER 4B 
Sequence of a 16kDa sexual stage and sporozoite surface antigen of 
Plasmodium reichenowi and comparison with Pfsl6 of 
Plasmodium falciparum 
Moelans, I.I.M.D., Lai, A.A., 
Konings, R.N.H. and Schoenmakers, J.G.G. 
Molecular and Biochemical Parasitology 50 (1992), 349-350 

Recently, we reported the characteristics of protein Pfsl6, a novel sporozoite 
and sexual stage specific surface antigen of the human malaria parasite Plas-
modium falciparum (1,2). Although the biological function of the protein is 
not yet known, preliminary investigations indicate that it might function as a 
sporozoite binding factor in hepatocyte invasion. Plasmodium reichenowi is a 
chimpanzee malaria parasite that is evolutionarily related to P. falciparum 
(3,4). Since these parasites have adapted to different hosts, comparison of 
the amino acid sequences of the 16 kDa proteins might uncover differences 
that could be significant in host-parasite interactions. 
The gene encoding the 16 kDa antigen Prsl6 from P. reichenowi was ampli-
fied from genomic DNA using primers deduced from the P. falciparum gene 
sequence (isolate NF54) (1,2). To eliminate sequencing errors caused by Taq 
DNA polymerase misincorporation, the nucleotide sequence was determined 
directly from amplified material (5). Comparison of genes Prsl6 and Pfsl6 
reveals that they are highly homologous at both the nucleotide (96%) and 
amino acid (94%) sequence level (Fig. 1). Interestingly, the differences in 
amino acid sequences between Prsl6 and Pfsl6 are entirely restricted to the 
amino acid sequences exposed to the extracellular surface (amino acid 
residues 23-103). The differences between the putative cytoplasmic domains 
(amino acid residues 127 to 160), i.e. hexanucleotide GAT.AAA (Asp-Lys; 
positions 141 and 142), and the conservative amino acid substitution at 
position 85 cannot be due to host differences because they exist between the 
amino acid sequences of the Pfsl6 antigens encoded by the P. falciparum 
isolates NF54 and GH1 from Ghana (2). The other differences, an extra 
glycine residue at amino acid position 67 and six mainly nonconservative 
substitutions, might reflect functional differences in host-sporozoite 
interaction and/or invasion. The binding characteristics of the extracellular 
domains of the Prsl6 and Pfsl6 antigens to primary human liver cells, and 
the inhibitory effects of antibodies raised against these domains on sporozoite 
invasion, are currently under investigation. 
From recent phylogenetic studies of the genus Plasmodium it has been 
concluded that, unlike the mammalian and human malaria species such as P. 
vivax, P. fragile, P. yoelli, or P. berghei, the origin of P. falciparum is 
from avian stock and that a recent event akin to lateral transfer was responsi-
ble for the introduction of this parasite into the human population (6). This 
conclusion is supported by our observations (1) that a homoloque of gene 
Pfsl6 is present in the avian parasite P. gallinaceum but absent from the 
human and rodent Plasmodium species P. vivax, P. berghei and P. yoelli. 
Similar observations have been made for Pfs25, an ookinete surface antigen, 
which is present in P. gallinaceum but absent in the parasites P. vivax, P. 
cynomolgi and P. knowlesi (7). The presence of a homologue of these genes 
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in P. reichenowi (this paper; 4) strongly suggests that the evolutionary 
history of P. reichenowi also is closely linked with that of the avian malaria 
species. 
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Fig. 1. Nucleotide sequence and deduced amino acid sequence of gene Prsl6 of 
Plasmodium reichenowi. The observed differences between these sequences and those of 
gene Pfsl6 of Plasmodium falciparum (isolate NF54) are indicated in bold face above and 
below the sequence. Amino acid and nucleotide residues that are absent in P. falciparum 
NF54 are asterisked and hyphenated, respectively. 
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CHAPTER 5A 
Induction of Plasmodium falciparum sporozoite-neutralising antibodies 
upon vaccination with recombinant Pfsl6 vaccinia virus and/or 
recombinant Pfsl6 protein produced in yeast 
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ABSTRACT 
Pfsl6 represents a sexual stage/sporozoite specific antigen of Plasmodium falciparum and 
is a potential candidate for a sporozoite-neutralising vaccine. To obtain more information 
on the function of Pfsl6 and to investigate its role during transmission and hepatocyte 
invasion, immunisation experiments were performed with both a Pfsl6 specific 
recombinant vaccinia virus and virus-like particles produced in yeast composed of the 
hepatitis В surface antigen (HBsAg) and antigen Pfsl6 fused to HBsAg. Upon 
transformation of yeast cells, harbouring a genomic copy of the HBsAg gene, with a 
plasmid carrying the fusion gene Pfsl6-HBsAg (Pfsl6-S) virus-like hybrid particles 
composed of HBsAg and Pfsl6-S were formed of a size similar to those present in human 
sera after infection with the hepatitis В virus. Cells infected with recombinant Pfsl6 
vaccinia virus synthesised a polypeptide of approximately 16 kDa that reacted with a 
Pfsl6-specific polyclonal antibody. Animals vaccinated with the yeast hybrid particles 
and/or recombinant vaccinia virus both produced Pfsl6 specific antibodies. These 
antibodies showed no transmission-blocking activity, but they efficiently diminished or 
abolished in vitro invasion of sporozoites into human hepatoma cells (HepG2-A16) and 
primary human hepatocytes. 
INTRODUCTION 
Sporozoites are the infective stage of the malaria parasite and are found in 
the salivary glands of female Anopheles mosquitoes. During feeding, 
mosquitoes inject sporozoites into the host's circulation where they rapidly 
invade hepatocytes and develop into thousands of merozoites. After rupture 
of hepatocytes, these merozoites initiate repeated cycles of erythrocyte 
infection associated with clinical disease. Irradiated sporozoites elicit 
protective immunity in rodents, monkeys and humans and led to the 
identification of CS and SSP2 proteins (1-5). There is now compelling 
evidence indicating that the immunity induced by irradiated sporozoites is 
mediated by anti-sporozoite antibodies, as well as CD4 + and CD8+ cells 
that recognise sporozoite-infected hepatocytes (6). CS protein has been the 
focus of most efforts to develop a pre-erythrocytic stage malaria vaccine. 
However, despite many efforts, thus far only a few volunteers have been 
protected with recombinant or synthetic CS vaccines (7,8). 
Recently, we reported the presence of the highly conserved 16 kDa protein 
Pfsl6 on the surface of both sexual stage parasites and sporozoites (9,10). 
Rabbit sera raised against a synthetic peptide and against recombinant fusion 
proteins produced in Escherichia coli (E. coli) recognise a 16 kDa antigen in 
protein extracts of gametocytes, macrogametes and sporozoites by Western 
blot analysis (9). By one- and two-dimensional Western blot analysis using 
Pfsl6 specific monoclonal antibodies it was demonstrated that these 16 kDa 
proteins are identical (unpublished data). By immunoelectron microscopy, 
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Pfsl6 was localised on the surface of sporozoites and in the parasitophorous 
vacuole membrane of gametocytes (9,11,12). 
We further investigated whether Pfsl6 is a candidate malaria vaccine antigen 
that might elicit protective antibodies that could neutralise sporozoite 
infectivity or block transmission. To begin development of suitable Pfsl6 
vaccines, we report in this study the expression of Pfsl6 or Pfsl6 fragments, 
in yeast and mammalian cells. Yeast provides a simple and inexpensive 
means for recombinant protein production (13). Very recently, the RTS,S 
vaccine produced in yeast, containing the hepatitis В virus envelope protein 
as a carrier for B-cell and T-cell epitopes of the central repeat region and the 
carboxy terminal region of the CS protein, has proven to be safe and 
immunogenic during a clinical study conducted in Thailand (14). Live 
attenuated viruses, such as vaccinia virus are attractive vectors for vaccine 
development because they are easily administered, inexpensive to produce 
and stress-resistant during transport. Vaccinia virus has been used for the 
production of a large number of antigens from pathogenic organisms, and in 
several cases vaccination with these recombinant viruses conferred immunity 
to a subsequent challenge (15,16). Viral vectors stimulate different arms of 
the immune system, which is valuable for vaccine development (17,18). 
Antisera were prepared with both recombinant vaccinia virus and a 
recombinant Pfsl6 fusion protein prepared from yeast. These sera were 
tested for their capacity to inhibit in vitro sporozoite invasion into human 
hepatoma cells and hepatocytes, and transmission-blocking activity. 
MATERIALS AND METHODS 
Construction of recombinant plasmids 
(i) Tcd5/16-S 
Recombinant plasmids were constructed and isolated by standard methods 
using E. coli MM294 (F, endAl, thi, hsdR17, supE44, lambda) as "host" 
(19). For the production of Pfsl6 specific fusion proteins in yeast the shuttle 
vector Tcd5 was used. It contains an expression cassette consisting of the 
yeast glyceraldehyde-3-phosphate dehydrogenase (TDH3) promoter fused to 
the gene coding for HBsAg followed by a yeast transcription termination 
region of the ARG3 gene. The Leu2 gene serves as a selection marker. 
Fig. 1. (A) Schematic representation of plasmid Tcd5/16-S. (B) Amino acid sequence of 
the fusion protein Pfsl6-S. It consists of the Pfsl6 antigen ( = = ) (devoid of the signal 
peptide'sequence (amino acids 1-19) and the putative membrane anchor and cytoplasmic 
region (amino acids 105-157)) fused to the hepatitis В surface antigen ( ). 
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PCKTCTTPAQ 
KYLWEWASVR 
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VQWFVGLSPT 
FCLWVYI 
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Both at the 5' and 3' ends of the expression cassette TY1 sequences were 
inserted (20) to achieve homologous recombination between the expression 
cassette and TY1 sequences present within the yeast genome. To create 
fusions between the Pfsl6 gene and the gene coding for the hepatitis В 
surface antigen (HBsAg) a PCR fragment coding for amino acids 20-104 of 
Pfsl6 was cloned into the unique Smal site of the shuttle vector Tcd5 (Fig. 
1A). The plasmid containing the Pfsl6 sequence was designated Tcd5/16-S. 
The resulting chimeric gene encodes a protein (Pfsl6-S) the deduced amino 
acid sequence of which is shown in Fig. IB. The Tcd5/16-S plasmid was 
digested with Xhol and the resulting fragments were separated by agarose gel 
electrophoresis according to standard procedures (19). The fragment 
Tcd5/16-S-.Xfa>I, containing the TY1, Leu2 and the expression cassette 
sequences, was then isolated by electroelution (19). Subsequently, 
Saccharomyces cerevisiae strain Y1295 (MATa, leu2-3, leu2-112), already 
containing 4-5 copies of the HBsAg gene in its genome, was transformed 
with the Tcd5/16-S-A7zoI fragment via the spheroplast transformation method 
described by Hinnen and coworkers (21). Stable transformants were selected 
by selection for leucine auxotrophy. The transformant containing both a copy 
of the Pfsl6-S fusion gene and 4-5 copies of the HBsAg gene was called 
Y1655 and the hybrid particles composed of HBsAg and Pfsl6-S (Pfsl6-
HBsAg fusions) were designated Pfsl6-S,S. 
(ii) Construction of recombinant vaccinia virus transfer vector pSCll/16 
As transfer vector plasmid pSCll was used. It contains a compound 
early/late promoter of moderate-strength, P 7 5, followed by a unique Smal 
restriction site and flanked by fragments (TK1 and TKr) of the vaccinia 
thymidine kinase (TK) gene (Fig. 2). It also contains the late vaccinia virus 
promoter P
u
, that is used for the expression of the E. coli lacZ reporter 
gene. The recombinant Pfsl6 specific transfer vector pSCll/16 was 
constructed via insertion of a PCR fragment, encompassing the complete 
coding information of Pfsl6, into the unique Smal site. Recombinants were 
constructed and propagated by standard methods (19). For the construction 
of recombinant viruses according to standard methods vaccinia virus strain 
WR, a gift of Dr. L. Boryciewicz (University of Cambridge, UK), was 
used. It was propagated and purified as reported previously (22). CV-1 cells 
infected with wild type vaccinia virus were transfected with calcium 
phosphate-precipitated plasmid (pSC 11/16) DNA (23). 
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Fig. 2. Schematic representation of the vaccinia virus transfer vector pSC 11/16. The lacZ 
gene located downstream of promoter p n was fused in frame to the ATG codon of the 
late gene encoding an 11 kDa polypeptide (25). A blunt-ended DNA fragment containing 
the entire coding sequence of Pfsl6 was inserted into the Smal site of pSCll to form 
pSCll/16. Expression of Pfsl6 is under control of the early/late promoter p75. 
For identification and purification of recombinant viruses TK selection and 
ß-galactosidase screening was used (23). TK-recombinants producing ß-
galactosidase were selected by plaque assay on RAT-2 cells (TK) in the 
presence of 5-bromo-deoxyuridine (BUdR) and X-Gal (60 μg/ml). Plaques 
were visualised after approximately 6 hours of incubation at 37°C. After two 
to three selection procedures, recombinant virus (vSC 11/16) was amplified in 
RAT-2 cells (22). CV-1 and RAT-2 cells were grown in Dulbecco's 
Modified Eagle's Medium (DMEM, GIBCO Laboratories) containing 10% 
fetal bovine serum (FBS) and for the TK" cells 25 μg of 5-bromo-
deoxyuridine (BUdR) per ml was added to the medium. 
Analysis of the synthesis of recombinant proteins in yeast 
Synthesis of the recombinant proteins Pfsl6-S and HBsAg was monitored by 
immunoblot analysis of total extracts using rabbit polyclonal antiserum 
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K37S8 (anti-Pfsl6) (9) and mouse monoclonal antibody, HBS1 (anti-
HBsAg), respectively. Preparation of crude cell extracts and immunoblot 
analysis was performed as described (24). 
Characterisation of yeast particles containing recombinant Pfsló specific 
fusion protein 
HBsAg synthesized in yeast is accumulated in particles similar in size as the 
22 nm particles found in human sera after hepatitis В infection which have a 
buoyant density of 1.18 g/cm3 (25). To study whether the recombinant 
Pfsl6-S fusion proteins and HBsAg synthesised in yeast Y1655 also 
accumulate in 22 nm particles, crude extracts of Y1655 yeast cells were 
subjected to CsCl equilibration centrifugation as described (24). In short, 
crude cell extract, equivalent to approximately 15 mg of cell protein, was 
mixed with 1.5 M CsCl in sodium phosphate buffer, pH 7.4, and 
centrifugated in a 50 Ti (Beekman) rotor at 45,000 rpm for 72 hours at 8°C. 
After centrifugation 0.5 ml fractions were collected by puncturing the bottom 
of the tube. Subsequently, 2 μ\ of each fraction was analysed for the 
presence of HBsAg via the radioimmunoassay AUSRIA II (Abbott 
Laboratories, USA) and 10 μΐ was used for immunoblot analysis to study the 
presence of the Pfsl6-S fusion protein and HBsAg antigen, utilising antisera 
K37S8 and HBS1, respectively. 
Expression of gene Pfsló using recombinant vaccinia virus vSCll/16 
To study the expression of gene Pfsl6 after infection with recombinant 
vaccinia virus vSC 11/16, a confluent RAT-2 cell monolayer was used. 48 
hours after infection cells were harvested by low-speed centrifugation and the 
pellet fraction was resuspended in 400 μ\ of SDS/sample buffer and heated 
for 5 min at 95°C. To establish whether a Pfsl6 protein of appropriate size 
was made immunoblot analysis was performed using K37S8 as antiserum. 
Isolation of gametocytes and sporozoites 
Isolation of sporozoites was performed using the urografin gradient method 
as described by van Pelt and coworkers (26). Gametocytes were isolated as 
described (9,27). 
Western blot analysis 
For Western blot analysis of sporozoite (SWB) and gametocyte (GWB) 
antigens, samples containing approximately 3.106 parasites were boiled for 5 
min in 25 μ\ of sample buffer (62.5 mM Tris-HCl; 2% SDS; 10% glycerol; 
5% 2-mercaptoethanol; 0.003% bromophenol blue, pH 7.2). Subsequently, 
the samples were loaded onto a 12.5% SDS-PAGE gel and electrophoresis 
was carried out according to standard methods (19,28). The samples were 
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then transferred to nitrocellulose by electroblotting as described (29). The 
blot was then washed for 5 min in PBST (phosphate buffered saline (PBS) 
supplemented with 0.1% Tween-20) followed by blocking of the unspecific 
binding sites by incubation for 1 h in PBST-buffer supplemented with 3% 
BSA. Visualisation of the respective antigens was performed as described 
(9). 
Indirect immunofluorescence assay (IFA) 
Sporozoites from salivary glands were counted and diluted to 1000 
sporozoites per 10 μ\ of PBS. Drops of 20 μΐ were pipetted in each of the 12 
wells of multitest slides, air dried and stored at -70°C. Sera were diluted in 
PBS and 20 μ\ of the appropriate dilutions were applied to the wells 
containing sporozoites. After 20 min incubation in a moist chamber at 37CC, 
the slides were washed thrice with PBS. Fluorescein-conjugated goat anti-
rabbit or rabbit anti-mouse IgG antiserum was then added at a dilution of 
1/50 (in 0.05% Evans Blue) and the slides were incubated for another 20 
min. After an additional wash in PBS, 50% glycerol in PBS was added to 
the samples and they were analysed by fluorescence microscopy. 
Suspension indirect immunofluorescence assay (SIFA) 
For SIFA, 100,000 sporozoites purified by the urografin gradient method 
were suspended in 10 μΐ of PBS and incubated at room temperature for 20 
min with the appropriate antiserum. Following low-speed centrifugation the 
sporozoites were washed twice with 100 μ\ of PBS prior to incubation for 20 
min at room temperature with 10 μΐ of goat anti-rabbit or rabbit anti-mouse 
FITC-conjugated antiserum at a dilution of 1/50 (in 0.05% Evans Blue). 
After several washings with PBS, samples of 10 μΐ (100,000 sporozoites) in 
PBS were applied to slides and covered by coverslips and they were analysed 
by fluorescence microscopy. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Microtiter plates were coated with 1 ^g/well of GST/B-D, a Pfsl6 encoded 
polypeptide fused to the C-terminus of Schistosoma japonicum glutathione S-
transferase, produced in E. coli (9). Assays were performed as described (9). 
Titers of 1:100 or less were considered negative. 
Sporozoite invasion in vitro 
Tests of inhibition of sporozoite invasion (ISI) were carried out both with 
human hepatoma (HepG2-A16) cells and with primary cultures of human 
hepatocytes, propagated on glass coverslips (diameter 15 mm). Primary 
cultures of human hepatocytes were obtained as described previously (30). 
HepG2-A16 cells were grown at 37°C in 5% C02 in air to a confluent 
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monolayer in DMEM supplemented with 2 mM glutamine, 10% fetal calf 
serum and 100 U each of penicillin and streptomycin per ml medium. The 
culture medium was then replaced by DMEM without supplements and 
(anti)sera were diluted in the appropriate medium and added to the cell 
cultures. To the HepG2-A16 cells (350,000) and primary human hepatocytes 
(175,000) 30,000 respectively 150,000 sporozoites were then added per 
coverslip and incubation was continued for 3 hours at 37°C in 5% C02. 
Subsequently, the coverslips were washed several times with PBS. The cell 
monolayers were then fixed with methanol (10 min), followed by three 
washes with PBS. Penetrated intracellular sporozoites surrounded by a 
membrane were revealed by an immunoperoxidase antibody assay using a 
monoclonal antibody to P. falciparum CS (3sp2) as described (26,31). All 
experiments were carried out at least in duplicate. 
Transmission-blocking assay (TB-assay) 
Mice and rabbit sera were tested for transmission blocking activity in a 
bioassay by membrane feeding of cultivated gametocytes of NF54 to female 
mosquitoes in the presence of test or control sera (32). 
Immunoelectron microscopy 
Immunoelectron microscopy was used to localize the Pfsl6 antigen in the 
exo-erythrocytic stages of P. falciparum. Immunoelectron microscopy was 
performed as described (33). 
Animals and immunisation 
Balb/c mice (M3 and M4) and New Zealand rabbits (R38 and R39) were 
immunised with purified recombinant yeast particles (Pfsl6-S,S) composed 
of the recombinant proteins Pfsl6-S and HBsAg. Alum was used as 
adjuvant. Rabbits were immunised via subcutaneous injection in weeks 0, 3 
and 6 with 50 ^g of recombinant protein. Mice were immunised in weeks 0, 
3 and 7 with 20 μg of yeast particles. Serum was obtained from the animals 
two weeks after the third immunisation (R38S3, R39S3, M3S3, M4S3). 
Rabbits R57 and R64 were inoculated intraveneously in weeks 0 and 7 with 
107-2.5xl07 plaque forming units of the recombinant Pfsl6 vaccinia virus 
vSC 11/16 and serum was obtained 2 weeks after the second inoculation 
(R57S2, R64S2). Several weeks after the third Pfsl6-S,S boost rabbit R39 
was also infected subcutaneously with 107 plaque forming units of the 
recombinant vaccinia virus and serum was collected 22 days after inoculation 
(R39v22). As controls, mouse (M2S2) and rabbit (R8S2) antisera raised 
against recombinant fusion proteins consisting of CS-epitopes and HBsAg 
produced in yeast (13) were used. Pre-sera from mouse Ml (M1S0) and 
rabbits R8, R38, R39, R57, R64 (R8S0, R38S0, R39S0, R57S0, R64S0) 
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were taken as controls from all mice and rabbits just before the first 
immunisations. All antisera were used in ELISA, Western blot analysis, 
IFA, SIFA, ТВ-assay and ISI. 
RESULTS 
Identification of recombinant proteins synthesised in yeast 
To study the expression of Pfsl6-S and HBsAg in yeast Y1655 cells cellular 
proteins were analysed by immunoblot analysis using both a monoclonal 
antibody HBS1, specific for the HBsAg monomer, and a polyclonal 
antiserum K37S8, raised against the recombinant Pfsl6 fusion protein 
produced in E. coli (9). As shown in Fig. 3 the monoclonal antibody HBS1 
reacted with two proteins with molecular weight of 22 and 32 kDa 
respectively, while the Pfsl6 specific polyvalent antiserum reacted only with 
the 32 kDa protein. From these results it can be concluded that in Tcd5/16-
S-Xhol transformed yeast Y1295 cells the recombinant proteins Pfsl6-S and 
HBsAg are produced. 
1 2 3 4 F'S- 3. Immunoblot analysis of recombinant proteins 
massMJai ^raf1"-^ -г— synthesised in Y1295 yeast cells transformed with 
expression cassette Tcd5/16-S-XftoI. Proteins that react 
with HBsAg specific monoclonal antibody HBS1 are 
shown in lanes 1 and 2. Proteins that react with Pfsl6 
specific antiserum K37S8 are shown in lanes 3 and 4. 
Per lane 50 jug of total cellular protein was applied. 
Studies on the expression of hepatitis В surface antigen coding sequences in 
yeast have demonstrated that these proteins spontaneously aggregate in virus-
like particles with a diameter of 22 ran which readily can be separated from 
other proteins by CsCl density gradient centrifugation (25) exhibiting a 
density of 1.2 g/cm3. These characteristics are also observed for the particles 
found in human patients after a hepatitis В virus infection. To study whether 
also the proteins Pfsl6-S and HBsAg are assembled in 22 nm particles crude 
cell extracts of Y1655 cells were subjected to CsCl equilibration 
centrifugation (24). After centrifugation fractions were collected by 
puncturing the bottom of the tube. Subsequently, part of each fraction was 
analysed by the radioimmunoassay AUSRIA II for HBsAg antigenic activity 
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and another part was analysed by Western blot analysis for the presence of 
Pfsl6 specific antigens (Fig. 4). In addition, the density of each fraction was 
determined. Since for recognition in the AUSRIA II assay the HBsAg 
antigen must have a native conformation, de data of Fig. 4A show that 
fractions 15-20 contain most of the native HBsAg. The average buoyant 
density of the particles present in these fractions was found to be 1.202. To 
estimate the efficiency of assembly of both HBsAg and Pfsl6-S into 22 nm 
particles, immunoblot analysis of the gradient fractions was also performed 
with sera HBS1 and K37S8 that recognise linear epitope(s) on the HBsAg 
and Pfsl6 monomers, respectively. Fig. 4B and 4C show that most of the 
HBsAg and Pfsl6-S proteins are found in the fractions 15-20, demonstrating 
that the results of the immunoblot analysis follow the data of the AUSRIA II 
radioimmunoassay (Fig 4A). From the results obtained from the 
immunological analysis and from the measurements of the refraction indeces 
it can be concluded that the proteins Pfsl6-S and HBsAg assemble into 22 
nm particles (Pfsl6-S,S) and as efficient as native HBsAg (25). 
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Fig. 4. CsCl gradient centrifiigation of crude cell extracts prepared from yeast Y1655 
cells producing recombinant Pfsl6-S and HBsAg proteins. Tube fractions are numbered 
from bottom to top. Fractions were analysed for their HBsAg activity by the 
radioimmunity assay AUSRIA II (A), and were analysed by immunoblot analysis using 
K37S8 (B) and HBS1 (C) to demonstrate the production of recombinant Pfsl6-S and 
HBsAg proteins. 
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Immunogenicity of Pfsl6-S,S particles 
To evaluate the immunogenicity of purified Pfsl6-S,S particles, mice and 
rabbits were immunised as indicated in Materials and Methods. 
Subsequently, serum samples were analysed for the presence of Pfsl6 
specific antibodies by an ELISA. Titers up to 1:16,000 were obtained (Table 
1). Western blot analysis showed that sera R38S3 and R39S3 specifically 
reacted with a 16 kDa protein present in total protein extracts of both 
gametocytes and sporozoites. Serum R8S2, which was raised against yeast 
particles containing HBsAg and CS epitopes, only reacted with the CS 
protein in a sporozoite Western blot. As indicated in Table 1 indirect 
immunofluorescence assays revealed that all Pfsl6 specific antisera reacted 
with sporozoites in an IFA and fluorescence on the surface was observed 
when the SIFA was performed with unfixed live sporozoites, although the 
intensities were less than obtained after staining with the CS specific antisera 
M2S2 and R8S2. As a control, pre-immune sera were used. They did not 
give any reaction on the Western blots and there was no fluorescense in IFA 
or SIFA (Table 1). From these results it can be concluded that as a result of 
vaccination with the Pfsl6-S,S particles Pfsl6 specific antibodies are 
induced. Moreover, the present study confirms and extents earlier 
observations that the Pfsl6 antigen is present on the surface of sporozoites. 
Production of Pfsló in recombinant vaccinia virus infected cells 
Expression of the heterologous gene in cells infected with recombinant 
vaccinia virus vSC 11/16 was analysed by Western immunoblots. Western 
blots were prepared of cell extracts and incubated with Pfsl6 specific 
polyclonal antiserum K37S8 (9). In recombinant vaccinia virus infected cells 
but not in uninfected cells or in cells infected with wild type virus, a protein 
with a molecular weight of approximately 16 kDa could be demonstrated 
(data not shown). 
Production of Pfsló specific antisera with recombinant vaccinia virus 
To determine whether the vaccinia virus recombinants were able to induce a 
specific and strong immune respons to the Pfsló protein, rabbits were 
infected twice with recombinant vaccinia virus vSCll/16. After collection 
the antisera (R57S2 and R64S2) were first analysed for the presence of Pfsl6 
specific antibodies by ELISA. As shown in Table 1 high antibody titers were 
reached. Subsequently, the antisera were analysed for the presence of 
antibodies reactive to Pfsl6 by Western blot analysis of whole lysates 
prepared from gametocytes and sporozoites (Fig. 5). 
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Table 1. Summary of reactivities of various mouse (MISO, M2S2, M3S3 and M4S3) and 
rabbit antisera (R8S0, R8S2, R38S0, R38S3, R39S0, R39S3, R39v22, R57S0, R57S2, 
R64S0 and R64S2) in ELISA, IFA, SIFA and immunoblotting with P. falciparum 
gametocyte and sporozoite proteins. 
SERUM 
MISO 
(pre-serum) 
M2S2 
(CS+HBsAg) 
M3S3 
(Pfsl6-S,S) 
M4S3 
(Pfsl6-S,S) 
R8S0 
(pre-serum) 
R8S2 
(CS+HBsAg) 
R38S0 
(pre-serum) 
R38S3 
(Pfsl6-S,S) 
R39S0 
(pre-serum) 
R39S3 
(Pfsl6-S,S) 
R39v22 
(Pfsl6-S,S 
+ vSCll/16) 
R57S0 
(pre-serum) 
R57S2 
(vSC 11/16) 
R64S0 
(pre-serum) 
R64S2 
(vSCll/16) 
< 
< 
< 
< 
< 
< 
< 
< 
ELISA 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
100 
100 
16,000 
4,000 
100 
100 
100 
2,000 
100 
1,000 
1.106 
100 
19,200 
100 
76,800 
IFA 
+ + + 
+ + 
+ + 
-
+ + + 
-
+ + 
-
+ + 
+ + + 
-
+ 
-
+ 
SIFA 
+ + + 
+ 
+ 
-
+ + 
-
+ 
-
+ 
+ + 
-
+/-
-
+ 
SWB* 
Pfsl6* CS* 
ND 
ND 
ND 
ND 
-
- + + + 
-
+ 
-
+ 
+ + 
-
+ + 
-
+ + 
GWB* 
ND 
ND 
ND 
ND 
-
-
-
+ + 
-
+ + 
+ + + 
-
+ + + 
-
+ + + 
The symbols -, +/-, +, ++ and + + + reflect an increasing intensity of reactions. 
*SWB=sporozoite Western blot analysis 
GWB=gametocyte Western blot analysis 
^Reactivity with Pfsl6 or CS protein 
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Table 2. Effect of various mouse (MISO, M2S2, M3S3, M4S3) and rabbit antisera (R8S0, R8S2, R38S0, 
R38S3, R39SO, R39S3, R39v22, R57S0, R57S2, R64S0, R64S2) on sporozoite invasion in HepG2-A16 
cells and human hepatocytes. More information about these sera is given in Materials & Methods. ISI is 
expressed as percentage of invasion reduction as compared to the pre-serum. 
SERUM 
MISO 1 
(pre-serum) 1 
M2S2 1 
(CS+HBsAg) 1 
M3S3 1 
(Pfsl6-S,S) 1 
M4S3 1 
(Pfsl6-S,S) 1 
R8S0 (pre-serum) 1 
R8S2 (CS+HBsAg) 1 
R38S0 1 
(pre-serum) 1 
R38S3 1 
(Pfsl6-S,S) 1 
R39SO 1 
(pre-serum) 1 
R39S3 1 
(Pfsl6-S,S) 1 
R39v22 1 
(Pfsl6-S,S 1 
-t-vSCll/16) 1 
R57S0 (pre-serum) 1 
R57S2(vSCll/16) 1 
R64S0 (pre-serum) 1 
R64S2(vSCll/16) 1 
dil. 
100 
200 
1,000 
2,000 
10,000 
100 
200 
1,000 
2,000 
10,000 
100 
200 
1,000 
2,000 
10,000 
100 
200 
1,000 
2,000 
10,000 
100 
100 
100 
1,000 
2,000 
10,000 
100 
1,000 
2,000 
10,000 
100 
1,000 
2,000 
10,000 
100 
1,000 
2,000 
10.000 
100 
1,000 
2,000 
10,000 
100 
100 
100 
100 
ISI 
HepG2-A16 
#inv.sp. 
72 
119 
151 
308 
355 
7 
4 
17 
64 
153 
ND 
ND 
70 
210 
262 
6 
20 
60 
330 
390 
90 
3 
168 
197 
209 
212 
55 
101 
129 
132 
178 
162 
160 
159 
31 
88 
98 
149 
7 
45 
72 
145 
85 
33 
34 
54 
%ISI 
0 
0 
0 
0 
0 
90 
97 
89 
79 
57 
ND 
ND 
54 
32 
26 
92 
83 
60 
0 
0 
0 
96 
0 
0 
0 
0 
67 
49 
38 
38 
0 
0 
0 
0 
83 
46 
38 
0 
96 
75 
61 
22 
0 
62 
0 
0 
dil. 
ISI 
prim, hepat. 
#inv.sp. %ISI 
1 : 100 
1 : 100 
1 : 100 
1 : 100 
64 
56 
36 
21 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
12.5 
44 
67 
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As shown in Fig. 5 Western blot analysis demonstrated that the antisera 
R57S2 and R64S2 reacted specifically with the 16 kDa protein as present in 
sporozoites and gametocytes. Furthermore, IFA and SIFA revealed that the 
antisera also reacted specifically with antigens present on fixed and live P. 
falciparum sporozoites (Table 1) respectively. Moreover, immunoelectron 
microscopy demonstrated the presence of the Pfsl6 antigen at the surface of 
sporozoites as well as at the outer surface of exoerythrocytic schizonts 
collected after invasion of HepG2-A16 cells by sporozoites (Fig. 6). No 
reaction was observed with the pre-sera R57S0 and R64S0. 
The results of an additional infection of rabbit R39 with recombinant 
vaccinia virus vSC 11/16 several weeks after the third Pfsl6-S,S boost, are 
also presented in Table 2. The ELISA results showed that a very high Pfsl6 
specific antibody titer was obtained when compared to the titers seen after 
immunisation with Pfsl6-S,S or vSCll/16 alone. Antiserum R39v22 also 
reacted with the Pfsl6 antigen on both a gametocyte and a sporozoite 
Western blot (Fig. 5). We could also demonstrate a strong reactivity of the 
serum with the surface of sporozoites in the IFA and SIFA. 
Fig. 5. Western blot analysis of protein extracts prepared from sporozoites (lane 1) and 
gametocytes (lane 2) using rabbit antiserum R57S2 (B), negative control serum R57S0 
(A), antiserum R39v22 (D) and control pre-serum R39S0 (C). Antiserum R57S2 was 
collected two weeks after the second inoculation with recombinant vaccinia virus 
vSCll/16. Antiserum R39v22 was recovered at day 22 after infection with recombinant 
vaccinia virus vSCll/16 of rabbit R39 which was already immunised thrice with yeast 
hybrid particles Pfsl6-S,S. 
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Fig. 6. Localisation of the Pfsl6 antigen by immunoelectron microscopy utilising 
antiserum L57S2. (A) Sporozoites in mosquito salivary gland, demonstrating the gold 
label abundantly present at the surface. (B) Sporozoite in close contact with a human 
hepatoma cell. (C) Liver stage parasite in HepG2-A16 cell after infection by sporozoites. 
Gold label is primarily associated with the outer surface of the exoerythrocytic schizont. 
Bars=0.4 μπι. 
Inhibition of sporozoite invasion (ISI) in vitro 
We used the inhibition of sporozoite invasion (ISI) into cultured cells assay 
(31,34) to investigate whether sera from mice and rabbits vaccinated with 
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yeast Pfsl6-S,S particles and/or recombinant vaccinia virus were able to 
neutralise sporozoite infectivity. Positive controls were antisera raised in 
mouse (M2S2) and rabbit (R8S2) against yeast particles containing CS and 
HBsAg epitopes. Antisera from mice (M3S3 and M4S3) and rabbits (R38S3 
and R39S3) immunised with yeast Pfsl6-S,S particles significantly reduced 
invasion of sporozoites into HepG2-A16 cells, although their capacity to 
reduce invasion was less than sera to CS protein (Table 2). However, sera 
M3S3 and M4S3 were significantly more active than serum M2S2 against CS 
protein. When sera from rabbits immunised with recombinant vaccinia virus 
vSCll/16 were tested by ISI, only R57S2 had ISI activity, whereas R64S2 
was inactive. However, the rabbit pre-serum R64S0 itself significantly 
lowered the numbers of invaded sporozoites (Table 2), which may have 
obscured R64S2 activity. When rabbit R39 previously immunised with 
recombinant yeast Pfsl6-S,S particles was boosted with recombinant vaccinia 
virus vSCll/16, the ISI activity of this antiserum (R39v22) increased and 
was similar to rabbit serum R8S2 against CS protein. This correlates with 
the efficient boosting capacity of the recombinant vaccinia virus shown by 
anti-Pfsl6 ELISA activities (Table 1). 
DISCUSSION 
A sporozoite vaccine is expected to block either sporozoite invasion of 
hepatocytes or its subsequent intrahepatic development. Identification of 
sporozoite ligands might permit development of vaccines that elicit antibodies 
that block ligand recognition of hepatocyte receptors. It is likely that a series 
of molecular interactions are critical for sporozoite invasion. CS protein 
Region I, and Region II found in both CS protein and TRAP have been 
shown to specifically bind to hepatoma cells in vitro, and antibodies to these 
regions block sporozoite invasion (35-37). Recently, van Pelt et al. (26) have 
suggested that P. falciparum sporozoite invasion of human hepatocytes 
involves two distinct membrane 20 kDa and 55 kDa proteins, although the 
sporozoite ligands have not been identified. The results reported here suggest 
that the highly conserved Pfsl6 protein found in both sexual stages and 
sporozoites (9,10) is also involved in sporozoite invasion. 
To obtain more information on the precise biological function of the 16 kDa 
protein and to explore its role as a vaccine candidate, immunisation studies 
were performed using recombinant Pfsl6 vaccinia virus, and a Pfsl6 
fragment fused to the HBsAg, and expressed as virus-like particles in the 
yeast Saccharomyces cerevisiae. In line with previous findings (9) all 
antisera reacted with a 16 kDa protein in Western blots prepared from 
gametocyte or sporozoite extracts. In the suspension immunofluorescence 
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assay, antibodies to the recombinant Pfsl6 product reacted with the surface 
of the sporozoite, suggesting that these sera recognised the authentic native 
Pfsl6 antigen. Furthermore, antibodies to the protein constructs specifically 
reduced in vitro invasion of human hepatoma HepG2-A16 cells and primary 
human hepatocytes. Of interest was our finding that mouse anti-Pfsl6 
antibodies were more active in blocking invasion of human hepatocytes than 
anti-CS protein antibodies. We have previously demonstrated that sera from 
human volunteers immunised with CS protein vaccines and protected to 
sporozoite challenge blocked sporozoite invasion of hepatoma HepG2-A16 
cells but not human hepatocytes (34). Thus, Pfsl6 may represent a candidate 
malaria vaccine designed to elicit sporozoite neutralising antibodies. 
Immune responses to Pfsl6 as assessed by ELISA, IFA, SIFA and ISI were 
strongly enhanced after recombinant vaccinia virus infection after the third 
boost with Pfsl6-S,S. This suggests that the recombinant yeast/vaccinia virus 
combination might be a good strategy to evoke high anti-Pfsl6 antibody 
titers. 
Immunoelectron microscopy experiments using antisera R57S2 and R64S2 
from rabbits infected with recombinant vaccinia virus confirm that Pfsl6 is 
localised on the surface of sporozoites (Fig. 6A) and appears to accumulate 
between hepatoma cell and the attached sporozoite (Fig. 6B). We also found 
that the Pfsl6 is localised on newly invaded sporozoites as well as 5 day P. 
falciparum liver stage parasites. The liver stages are attractive targets (38-40) 
for vaccine development because they are susceptible for immune attack for 
much longer than sporozoites, i.e. at least five days compared to a few 
minutes (40,41). Moreover, both CD4+ and CD8+ Τ cells have been 
shown to attack malaria-infected hepatocytes, either by direct cytotoxicity or 
inderectly by cytokines, suggesting that P. falciparum epitopes are expressed 
on the surface of infected hepatocytes in association with MHC Class I or II 
molecules (40,42-44). The presence of Pfsl6 during P. falciparum liver 
stage development suggests that Pfsl6 vaccines could also elicit cytotoxic Τ 
cell responses directed to P. falciparum-infected hepatocytes. 
None of the antisera showed transmission-blocking activity, indicating that 
Pfsl6 probably does not play a critical role in the process of transmission of 
the parasite from the human host to the mosquito vector. Comparable results 
were observed in previous Pfsl6 immunisation experiments (9) and this is 
also in agreement with Baker et al. (1994) and Bruce et al. (1994) who 
demonstrated that Pfsl6 is located on the parasitophorous vacuole membrane 
of the gametocyte and not on the plasma membrane of gametes (11,12). 
Since antigens on the gamete plasma membrane are the most likely targets of 
transmission-blocking antibodies, the absence or low expression of the Pfsl6 
antigen on the gamete plasma membrane may explain lack of transmission-
blocking activity. However, the location of Pfsl6 on the parasitophorous 
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vacuole membrane suggests that this antigen may play a role during 
gametocytogenesis or is involved in the emergence of macrogametes from 
the parasitophorous vacuole membrane. The possible role of Pfsl6 in these 
processes is currenly under investigation. 
In conclusion, the present study confirms that the Pfsl6 antigen is expressed 
on P. falciparum sporozoites. Pfsl6 may be involved in sporozoite invasion 
of hepatocytes since Pfsl6 specific antibodies reduced sporozoite invasion 
into human hepatoma cells and human hepatocytes. Since Pfsl6 is also 
expressed during P. falciparum liver stage development, Pfsl6 may represent 
a candidate antigen for malaria vaccine development. 
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CHAPTER 5B 
Large-scale production of recombinant Plasmodium falciparum antigen 
Pfsl6 in Escherichia coli 
Moelans, I.I.M.D., Baerends, R.J.S., Stevanovic, S., Mulder, L., 
Schoenmakers, J.G.G. and Konings, R.N.H. 
Experimental Parasitology, submitted for publication 

ABSTRACT 
We have developed a new system for the large-scale heterologous synthesis and one-step 
purification of antigen Pfsl6 of the human malaria parasite Plasmodium falciparum (P. 
falciparum) in Escherichia coli (E. coli). The recombinant protein consists of the 
authentic amino acid sequence of native Pfsl6 fused at its carboxy-terminal end to a poly-
histidine tag. We demonstrate that large amounts of recombinant Pfsl6 easily can be 
purified by nickel affinity chromatography and that the recombinant protein is appropriate 
for large-scale epidemiological studies to demonstrate Pfsl6 specific antibodies. 
INTRODUCTION 
The highly conserved sporozoite and sexual stage specific antigen Pfsl6 of 
P. falciparum is a prominent vaccine candidate to control malaria (1,2). 
Recently, it was demonstrated that Pfsl6 specific monoclonal and polyclonal 
antibodies recognize a 16 kDa antigen in protein extracts of sexual stages 
and sporozoites by Western blot analysis (2, Moelans et al., submitted). By 
immunoelectron microscopy the presence of Pfsl6 could also clearly be 
demonstrated in the parasitophorous vacuole membrane of sexual stages and 
on the surface of sporozoites (2,3). Moreover, Pfsl6 specific messenger 
RNA has been detected in gametes, gametocytes (2) and sporozoites 
(unpublished data). In order to obtain workable quantities of Pfsl6 specific 
peptides for fundamental research and vaccine development, fragments of 
Pfsl6 have been cloned and expressed in Saccharomyces cerevisiae (5. 
cerevisiae) and E. coli. Recently, a Pfsl6 fragment fused to the hepatitis В 
surface antigen (HBsAg) has been produced in S. cerevisiae (Moelans et al., 
submitted). It was demonstrated that large quantities of the recombinant 
Pfsl6 protein easily could be purified and that antisera raised against this 
recombinant protein could diminish or abolish the in vitro invasion of human 
hepatoma cells and primary hepatocytes by P. falciparum sporozoites. The 
recombinant fusion protein is, however, not suitable for serological studies, 
because of the likely presence of HBsAg specific antibodies in human sera. 
Furthermore, Pfsl6 encoded polypeptides fused to the C-terminus of the 
Schistosoma japonicum glutathione S-transferase (GST) have been produced 
in E. coli (2,4). Most GST-Pfsl6 fusion proteins were, however, largely 
insoluble, so that the advantage conferred by the fusion partner in providing 
a simple affinity chromatography procedure to facilitate purification could 
not been used (unpublished data). Moreover, Baker et al. (3) have used 
vector pKK223-3 for high level expression of Pfsl6 in E. coli and found the 
recombinant Pfsl6 protein to be insoluble in the absence of SDS. To 
circumvent these difficulties a new expression system was developed for the 
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large-scale heterologous synthesis of Pfsl6 in E. coli such that (all) 
recombinant proteins easily can be purified and used in distinct applications, 
serological studies in particular. A plasmid expression vector has been 
constructed that directs the synthesis in E. coli of Pfsl6 proteins that only 
contain an additional stretch of six histidine residues at their C-terminal end, 
thus enabling their single-step purification by chelate affinity 
chromatography. To identify the N-terminal amino acid of Pfsl6 N-terminal 
amino acid sequence analysis of immunoaffinity-purified gametocyte Pfsl6 
antigen was performed, since it has been proposed that Pfsl6 contains a 
putative N-terminal signal sequence. A Pfsl6 fragment devoid of the signal 
peptide sequence was cloned in expression vector pQE17, because it is 
generally advisable to delete or otherwise substitute the coding region for 
eukaryotic signal peptides by prokaryotic signal peptides for optimal 
expression of eukaryotic membrane proteins in prokaryotic expression 
systems. 
MATERIALS AND METHODS 
Isolation of gametocytes 
Mature P. falciparum (NF54) gametocytes were cultivated in a semi-
automated suspension culture system (5). Isolation of gametocytes was 
performed as described (2). Washed, pelleted parasite preparations were 
stored frozen at -70°C. 
Purification of Pfsl6 from gametocytes and N-terminal amino acid 
sequence analysis 
Frozen gametocytes (1.108) were suspended in an extraction buffer 
containing 50 mM Tris-HCl (pH 8.6) and 150 mM NaCl. After 5 min of 
incubation on ice, cells were lysed by sonication. The samples were clarified 
by centrifugation and the resulting supernatant was immediately incubated for 
1 h with 100 μΐ of proteinA Sepharose CL-4B to which monoclonal antibody 
32F717 was coupled (according to the manufacturer's instructions, 2 mg of 
protein was coupled to 1 ml of swollen gel). Immune complexes were 
subsequently washed 5 times with 50 mM Tris-HCl pH 8.6, 150 mM NaCl, 
prior to subjecting to SDS-PAGE under reducing conditions (6,7). After 
electrophoresis, the gel was soaked for 5 min in electroblotting CAPS-buffer 
(10 mM 3-cyclohexyl-amino-l propane sulfonic acid, 10% methanol, pH 11) 
for 5 min. Meanwhile a poly(vinylidene difluoride) transmembrane 
(Immobilon-P) was wetted for a few seconds with 100% methanol and then 
transferred to the blotting buffer. Electroblotting (50 V) was completed after 
30 min at room temperature. The Immobilon-P matrix was removed from the 
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transblotted sandwich and rinsed with water before staining. Protein samples 
on the Immobilon-P transmembrane were visualised with 0.1% Coomassie 
Brilliant Blue in 1% acetic acid/40% methanol. The membrane was destained 
by soaking in a mixture of methanol and water (1:1, v/v). Then, the 
Immobilon-P membrane was thoroughly rinsed with water, and the bands of 
interest were excised with a clean razor blade. N-terminal amino acid 
sequence analysis was performed by Edman degradation using an ABI 
Model 477 A sequenator. 
Construction of expression vector pQE17-16 
For cloning and expression of the Pfsl6 gene the commercially available 
QIAexpress system was used (F. Hoffmann-La Roche Ltd, Basel, 
Switzerland). To facilitate protein purification by metal chelate affinity 
chromatography the recombinant protein was engineered to contain a six 
residues long histidine tail at the carboxy terminus. For in frame fusion 
with both the start codon of the DHFRS gene and the hexa-His region the 
expression vector pQE17 was linearized with Bgftl and a blunt-ended site 
was generated with T4 DNA polymerase. The remaining parts of the 
DHFRS gene were then almost completely removed (except for the first 
two codons) by ВатШ digestion. Since N-terminal amino acid sequence 
analysis of the Pfsl6 antigen have revealed that the amino acid sequence of 
the native protein starts at amino acid 26 of the primary translation product, 
a Pfsl6 gene fragment devoid of the signal peptide sequence was inserted 
in a proper orientation in the expression vector pQE17 (Fig. 1). First, a 
Pfsl6 PCR fragment was generated from genomic P. falciparum DNA by 
P C R u s i n g p r i m e r 2 9 2 ( s e n s e : 5 ' -
CAACATGAATATTCGAAAGTTCATACC-3') and primer 399 (antisense: 
5'-AGAATCATCTCCTTCGTCTTCTTC-3') as described (1). The 
fragments were precipitated with ethanol, digested with ВатШ, purified on 
an 1% agarose gel and isolated according to standard procedures (8). By 
this a truncated Pfsl6 fragment (coding for amino acids 38-157) was 
generated, because the Pfsl6 gene contains an internal ВатШ restriction 
recognition site. Subsequently, the purified DNA fragment was ligated into 
the pQE17 vector. Recombinant plasmids (pQE17-16B) were transformed 
in E. coli strain Ml 5 (nalsstrsriflac"ara'garmtrF"recA+uvr+) harboring 
plasmid pREP4. Transformants were selected after restriction analysis of 
plasmid DNA. Then, a synthetic ВатШ/ВатШ fragment coding for amino 
acids 26-37 of Pfsl6 was cloned into the ВатШ site of plasmid pQE17-
16B. The recombinant plasmids (pQE17-16) were again transformed in E. 
coli strain Ml5 harboring plasmid pREP4. 
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R R a S I I , C e . . H I 
pQE17-ie 
3621 bp 
• Ж ^ в« 
L Bgtll 
(B) MRGSDANDKAKKPAGKGSPSTLQTPGSSSGASLHAVGPNQGGLSPGLSGK 
DSADKMPLETQLAIEEIKSLSNMLDKKTTVNRNLIISTAVTNMIMLIILS 
GIVGFKVKKTKNADDDKGDKDKDKDNTDEGDEGDDSHHHHHH 
Fig. 1. (A) Schematic presentation of the construction of the Pfsló-Hi^ expression 
plasmid pQE17-16. The Pfsl6 coding region was amplified by PCR using a pair of 
primers, and genomic P. falciparum NF54 DNA as template. The PCR-amplified DNA 
fragment was digested with BamHI and ligated into the pQE17 plasmid. Then, a synthetic 
BamHl/BamHl fragment coding for amino acids 26-37 of Pfsl6 was cloned into the 
BamHI site of plasmid pQE17-16B. (B) Amino acid sequence of the recombinant His-
tagged Pfsl6-His6 protein. 
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The construct with the correct orientation and the entire sequence of the 
construct were verified by nucleotide sequence analysis (9). 
Large-scale synthesis of recombinant protein Pfsl6-His6 
For production of recombinant protein Pfsl6-his6, cells (500 ml) were grown 
to a density of A600=0.7 in LB medium. Then, the expression of the 
recombinant gene was induced by the addition of isopropyl-ß-D-
thiogalactopyranoside (IPTG) to a final concentration of 2 mM and 
cultivation was continued for another 3 hours. Protein samples were 
fractionated by SDS-PAGE and analysed by Coomassie blue staining. 
Identity of recombinant protein Pfsl6-His6 was verified by immunoblotting 
using Pfsl6 specific antisera. 
Purification of the recombinant protein 
Purification of the recombinant protein by affinity chelation chromatography 
on nickel colums was carried out according to the instructions of the 
supplier. Cells from a 0.5 litre of culture were harvested by centrifugation 
and the proteins were extracted with 30 ml of buffer A (6 M guanidinium 
chloride, 0.1 M Na-phosphate, 0.01 M Tris/HCl, pH 8.0). The lysate was 
centrifuged for 15 minutes at 10,000xg at 4°C and the supernatant was 
percolated over a column consisting of 3 ml resin, previously equilibrated in 
buffer A. Subsequently, the column was washed stepwise with 50 ml of 
buffer A, 50 ml of buffer В (8 M urea, 0.1 M Na-phosphate, 0.01 M 
Tris/HCl, pH 8.0) and 50 ml of buffer В with a pH of 6.5. Then the 
recombinant protein was eluted with buffer В at pH 4.5. After elution the 
protein solution was dialyzed extensively against PBS. 
Serum samples 
Serum samples were obtained in a sero-epidemiological malaria study in 
Cameron. Serum specimens of 80 malaria patients (age range 0.66-53 years) 
were assayed for Pfsl6 specific IgG antibodies. 
Enzyme-linked immunosorbent assay (ELISA) 
The occurence of Pfsl6 specific antibodies was determined in an ELISA 
assay. The procedure for testing reactivity against recombinant Pfsl6 protein 
has previously been described (2). Briefly, 96 well microtiter plates were 
coated with 0.3 μ% of purified recombinant Pfsl6-His6 protein for 2 h at 
37°C. Subsequently, 100 μ\ of human sera, diluted 1:500 in PBST (PBS 
supplemented with 0.1% Tween-20) was added to the wells and incubated 
for 1 h at room temperature. Pfsl6 specific antibodies were detected by 
incubation with peroxidase-labelled goat anti-human IgG for 1 h at room 
temperature. Washings between incubation steps were performed with PBST. 
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As substrate tetramethylbenzidine was used. On the basis of previous tests an 
optical density (450 ran) > 0.2 was set as the cut-off value for a positive 
reaction. 
RESULTS and DISCUSSION 
Purification and N-terminal amino acid sequence analysis of native Pfsló 
Native Pfsl6 was isolated at high purity from gametocytes by immunoaffinity 
chromatography as described in Materials and Methods. The isolated Pfsl6 
antigen could clearly be visualised on the preparative Immobilon-P matrix by 
Coomassie Brilliant Blue staining (data not shown). After amino acid 
sequence analysis, the sequence of the first fifteen amino acids of the native 
immunoaffinity-purified Pfsl6 antigen was found to be 
DANDKAKKPAGKGSP. This strongly suggests that the cleavage site for 
the signal peptide is located between amino acids 25 and 26 of the Pfsl6 
proprotein. Since we already have demonstrated that the Pfsl6 proprotein is 
incompletely processed in E. coli (unpublished results), a Pfsl6 fragment 
without signal peptide sequence and coding for the native polypeptide was 
cloned into the expression vector pQE17 to obtain optimal production of the 
recombinant Pfsló protein in E. coli as shown in Fig 1. 
Expression and purification of recombinant Pfsl6-His6 protein 
Extracts from induced and non-induced bacterial cultures containing the 
expression vector pQE17-16 were analysed by SDS-PAGE. Fig 2A shows 
the time course of expression of Pfsl6-His6 in pQE17-16 transformed E. coli 
cells (lanes 2-6). A novel protein band became visible after 30 minutes 
following the addition of the inducer IPTG (lane 3). The amount of this 
protein increased considerably within 1.5 h (lane 4) and reached a maximum 
after about 3 h (lanes 5 and 6). Western blot analysis showed that the protein 
identified by Coomassie blue staining reacted specifically with Pfsl6 specific 
monoclonal and polyclonal antibodies, demonstrating that the protein indeed 
represents the recombinant Pfsl6 product (data not shown). 
After purification of the Pfsl6-His6 protein by affinity chelation 
chromatography on a nickel column, SDS-PAGE analysis of the eluted 
protein revealed that the recombinant polypeptide is for 90% pure (Fig 2B) 
and approximately 0.5-1 mg of recombinant protein could be recovered from 
a 0.5 litre of cell culture, demonstrating that the His-tag at the C-terminus of 
Pfsl6 enabled the purification of the recombinant protein from bacterial 
extracts by a simple, one-step procedure, with very good overal yield and 
high purity. 
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Fig. 2. SDS-PAGE analysis of recombinant Pfslo-His^ protein produced in E. coli. (A) 
Time course of induction. pQE17-16 transformed E. coli cells were grown to an 
A6O0=0.7 and induced with 2 mM IPTG for different time periods. Lanes: 2: no 
induction; 3: 30 minutes; 4: 1.5 h; 5: 3 h; 6: 5 h. Subsequently, total protein extracts 
were prepared. (B) Affinity-purified Pfsl6-His6 produced in IPTG-induced cultures. Total 
protein and purified protein was fractionated on a 12.5% Polyacrylamide gel and stained 
with Coomassie blue. M, size markers (in kDa) in lane 1. Arrowhead indicates the 
position of migration of the Pfsló-His^ protein. 
Screening of sera for the presence of Pfsló-specific antibodies 
Repeated P. falciparum infections generally lead to the gradual acquisition of 
a nonsterile immunity in adults living in malaria-endemic areas. Although the 
mechanisms underlying this immunity are not properly understood and 
antibodies are not probably the exclusive molecules for evoking protection 
against malaria parasites, the importance of the humoral response in the 
defense against P. falciparum infections has clearly been demonstrated in the 
pionering work of Cohen et al. (10). Until now, no serological studies have 
been described in which the frequency of occurence of Pfsl6 specific 
antibodies in the human malaria patients population have been identified. 
Therefore, the recombinant polypeptide Pfsl6-His6 synthesised and purified 
with the aid of the E. coli QIAexpress system, as described above, was used 
in a serological study to test the utility of the recombinant protein in large-
scale epidemiological studies. Eighty serum samples from different-aged 
malaria patients infected with P. falciparum were analysed for the presence 
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66- 3 
4 5 0 
31.0 
21.5 
14.4 
of Pfsl6 specific antibodies. As shown in Table 1, the prevalence of Pfsl6 
specific antibodies in the population investigated was approximately 63%. 
The antibody levels, however, varied considerably between the individuals. 
Furthermore, the development of an anti-Pfsl6 response in the investigated 
population is not age-related; both the prevalence of Pfsl6 specific antibodies 
and mean antibody levels were almost the same in the four age-groups. As a 
control, sera from adults without a malaria history were tested for a positive 
reaction in the same ELISA assay. These sera always had an absorbance 
value <0.2, indicating that no cross-reacting antibodies were present in 
these sera. These results demonstrate that the recombinant Pfsl6-His6 is an 
appropriate antigen for large-scale epidemiological studies to identify Pfsl6 
specific antibodies. Moreover, although further serological studies are 
required to identify the occurrence of Pfsl6 specific antibodies in different 
endemic areas and to investigate the role of Pfsl6 specific antibodies in 
natural acquired immunity, the present study also clearly demonstrates that in 
an endemic area of continuous high malaria transmission humoral responses 
against the Pfsl6 antigen are produced. 
Table 1. Age-specific mean antibody responses for the Pfsló-Hise polypeptide. The mean 
antibody response of all sera was used for arbitrarily dividing the population into two 
groups, high and low responders, who had antibody responses greater than and less than 
the mean response, respectively. Donor sera with an absorbance value (450 nm) < 0.2 
were considered non-responders. 
High responders Low responders Non-responders 
Age no. pos/ %pos. no. pos/ %pos. no. pos/ 
no.test. no.test. no.test. 
0 - 4 
5 - 9 
10 - 19 
à 20 
12/27 
3/12 
5/25 
4/16 
44% 
26% 
20% 
25% 
7/27 
4/12 
10/25 
6/16 
26% 
33% 
40% 
37% 
8/27 
5/12 
10/25 
6/16 
30% 
41% 
40% 
38% 
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ABSTRACT 
Pfsl6 represents a sexual stage/sporozoite specific antigen of the malaria parasite 
Plasmodium falciparum and is a potential candidate for a sporozoite-neutralising vaccine. 
To determine whether the Pfsl6 antigen can induce humoral as well as cellular immune 
responses, six different congenie mouse strains were immunised with virus-like particles 
(Pfsl6-S,S), produced in yeast, composed of the S-antigen of the hepatitis В virus and of 
a Pfsl6 fragment (amino acids 20-104) fused to the hepatitis В S-antigen. Specific 
antibody production, lymphocyte proliferation and Delayed Type Hypersensitivity 
response was observed in all six congenies, demonstrating that the Pfsl6 antigen is able to 
induce both humoral and cellular immune responses, regardless of MHC. All antisera 
diminished specifically the in vitro invasion of HepG2-A16 by sporozoites. 
INTRODUCTION 
Much effort has been invested to develop vaccines against different life cycle 
stages of the human malaria parasite Plasmodium falciparum (P. falciparum). 
Induction of protective immunity against sporozoites and liver stages is one 
of the main goals in the development of a malaria vaccine (1,2). In theory a 
protective immune response against sporozoites can be mediated by 
antibodies, but evidence is accumulating that cellular immunity also plays an 
important role in the protection against sporozoite-induced malaria (2-15). 
This stresses the importance of identifying epitopes on sporozoite/liver stage 
antigens that are recognised by Τ cells. Τ cells, in contrast with В cells, 
recognise peptide fragments of antigens which have been produced by 
antigen presenting cells (APC). These APC present antigenic peptides to 
CD4+ and CD8+ Τ cells in association with class II or class I molecules of 
the Major Histocompatibility Complex (MHC), respectively (3). Due to this, 
the ability of an antigenic peptide to interact with a class I or class II 
molecule together with the availability of Τ cell Receptors specific for these 
peptide/МНС complexes determines the quality of the immune response 
(4,5). Moreover, В cells are dependent on the help provided by antigen-
specific CD4+ Τ lymphocytes for the production of high affinity IgG 
antibodies to most antigens. An ideal vaccine, therefore, consists of peptides 
which are able to activate both Τ and В cells in all individuals independent 
of their genetic background (MHC). 
Here, we study the ability of the sexual stage/sporozoite-specific Pfsl6 
antigen of P. falciparum to induce cellular and humoral immune responses in 
six congenie mouse strains. These mice have the same genetic background 
(BIO), but differ in their МНС-molecules (mouse MHC = H-2). 
We analysed the Pfsl6-specific immune response using different assays. 
Antibodies were quantified using an ELISA and were functionally tested in 
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vitro in an Inhibition Sporozoite Invasion (ISI) assay. Τ cell response was 
measured in vitro by a Τ cell proliferation assay and in vivo by a Delayed 
Type Hypersensitivity (DTH) reaction. In each case, six different congenie 
mouse strains were immunised with virus-like particles (Pfsl6-S,S), 
produced in yeast, composed of the S-antigen of the hepatitis В virus 
(HBsAg) and of a Pfsl6 fragment (amino acids 20-104) fused to HBsAg. 
Our data demonstrate the presence of at least one В cell epitope and at least 
one Τ cell epitope on Pfsl6. Moreover, all different congenie strains were 
able to mount a cellular and humoral immune response to Pfsl6, suggesting 
that the genetic background of an individual is not of crucial importance in 
the anti-Pfsl6 response. 
MATERIALS AND METHODS 
Mice 
Female BIO congenie mice were housed in our central animal facility and fed 
a standard diet and water ad lib. At the start of the experiments mice were 6 
weeks old. We used the following congenies: BIO.A (H-2a), B10.BR (H-2k), 
B10.D2 (H-2d), B10.G (H-2g), B10.S (H-2S) and C57B1/10 (H-2b). 
Τ cell proliferation assay 
Mice were primed with yeast hybrid Pfsl6-S,S particles (80 /xg/ml), 
composed of the S-antigen of the Hepatitis В virus (HBsAg) and of a Pfsl6 
fragment (amino acids 20-104) fused to HBsAg, emulsified in Freund's 
Complete Adjuvant (FCA), dead gametocytes (lO'/ml) or, as controls, with 
yeast particles composed of HBsAg (16) (80 /xg/ml), and with FCA alone. 
Mice were injected with 50 μΐ of emulsion in each of the forepaws and 
draining lymph nodes were aseptically removed 10 days thereafter. Single 
cell suspensions were made in RPMI 1640 supplemented with 10% (v/v) 
heat inactivated fetal calf serum and 40 μg/πú gentamycin (—complete 
medium) (all Flow laboratories, McLean, VA, USA) with a density of 2x 
106 cells/ml. Cells (100 μΐ/well) were incubated in 96-well roundbottom 
microtiter plates (Costar) with the Τ cell mitogen Concanavalin A (positive 
control), HBsAg, GST/B-D (recombinant Pfsl6 glutathion S-transferase 
(GST) fusion protein produced in E. coli) (17), gametocytes, sporozoites 
(isolated as described previously) (17) or with medium alone in a total 
volume of 200 μΐ. After 3 days, 37 kBq 3H-thymidine (Amersham, sp.act. 
0.7-1.1 χ 108 MBq/mmol) was added per well and incubation was continued 
at 37°C for another 16 hrs. Subsequently, cells were harvested onto glass 
fiber filters and the incorporated radioactivity was counted in a liquid 
scintillation counter. All values represent the mean of triplicate cultures. 
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Delayed Type Hypersensitivity (DTH) reaction 
Mice were immunised with hybrid Pfsl6-S,S particles emulsified in FCA (80 
/tg/ml). On day 0 they were injected with 50 μ\ in each forepaw and on day 
7 they were boosted by injection of 2x 100 μΐ of the same emulsion 
subcutaneously. On day 28, 1 μg of an in Escherichia coli produced Pfsl6 
encoded polypeptide (GST/B-D) fused to the C-terminus of the Schistosoma 
japonicum glutathione S-transferase (GST) was injected into the pinna of the 
right ear (17). As a control, 1 μg GST (17) was injected into the left ear. 
Thirty hours thereafter, ear swelling was measured using an industrial 
caliper. All groups consisted of 5 mice. 
Analysis of anti-Pfsl6 antibodies 
Mice (5 mice per group) were immunised as under DTH and were bled from 
the retro-orbital plexus on day 35. Blood was allowed to clot for 2 hours at 
room temperature and the resulting sera were tested in an ELISA and on 
gametocyte Western blots as described previously (17). The sera were also 
tested in a standard Inhibition Sporozoite Invasion (ISI) assay using HepG2-
A16 cells as described elsewhere (18-20). 
RESULTS 
Genetic restriction of the Pfsló-specific Τ cell response 
Vaccine-candidates must preferentially be able to induce an immune response 
in all individuals, independent of their genetic background. To analyse 
whether the Pfsl6 antigen of P. falciparum was able to induce a Τ cell 
response regardless of MHC, we immunised six congenie mouse strains as 
described in Materials and Methods with yeast hybrid particles Pfsl6-S,S 
emulsified in FCA. The results of a representative experiment out of 3 are 
shown in Table 1. All mouse strains displayed a similar response to Pfsl6. 
All Pfsl6-S,S-primed strains responded to gametocytes (Table 1) and Pfsl6-
S,S-primed C57B1/10 mice also responded to sporozoites (Table 2; only 
performed with C57B1/10), thus demonstrating that Pfsl6-induced immunity 
can be boosted by different developmental stages of the parasite. 
Immunisation with 107 gametocytes induced a Pfsl6-specific Τ cell response 
in all six congenie strains albeit generally somewhat lower than the one 
resulting from Pfsl6-S,S priming (data not shown). Immunisation with FCA 
alone or with recombinant HBsAg produced in yeast did not result in 
priming of Pfsl6 responsive Τ cells (data not shown), although Τ cells from 
FCA primed mice sometimes proliferated to parasites (gametocytes and 
sporozoites). This non-specific response, however, was always significantly 
lower than the specific one (Table 2). 
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Table 1. Proliferative responses of Pfsl6-pnmed lymph node cells of 6 congenie mouse 
strains. 
medium 
ConA.2 
gcflO4 
10s 
GST/B-D.2 
6 
B10.A 
521 
112 
5 
7 
14 
26 
BIO BR 
419 
100 
2 
5 
9 
16 
B10D2 
371 
88 
3 
6 
10 
16 
B10.G 
528 
103 
5 
6 
10 
17 
BIOS 
536 
109 
2 
3 
6 
10 
C57B1/10 
339 
124 
7 
12 
21 
33 
Medium is given as cpm, other values as stimulation index ConA and GST/B D (in E coli produced Pfsl6 
encoded polypeptide fused to the C-terminus of the Schistosoma japomcum glutathione S-transferase (GST)) 
are in ng/ml, get (gametocytes) in #/well Values represent the mean of triplicate cultures, the standard 
deviation was always less than 10% Results are obtained from a pool of two mice per group Immunisation 
with FCA alone or with HBsAg did not resulted in gametocyte- or Pfslô-challenged Τ cell responsiveness 
Table 2. Proliferative responses of Pfsl6-S,S-pnmed lymph node cells of C57B1/10 mice. 
#1 #2 #3 Ctrl 
medium 19 23 16 21 
ConA:2 100 73 132 85 
get 10s 15 18 21 6 
spora: 10s 37 15 35 9 
Hl, ÏÏ1 and #3 represent individual mice immunised with yeast Pfsl6-S,S hybrid particles emulsified in 
FCA Ctrl represents a mouse immunised with FCA alone Medium is given as cpm, other values as 
stimulation index ConA is in ^g/ml, get (gametocytes) and sporo (sporozoites) in #/well Values represent 
the mean of triplicate cultures, the standard deviation was always less than 10% 
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The increased polyclonal lymphocyte activation by P. falciparum parasites as 
reflected by increased 3H-thymidine incorporation has already been reported 
(12). It has been proposed that crude P. falciparum antigen preparations may 
contain mitogenic components. 
Delayed Type Hypersensitivity (DTH) reaction to Pfsló 
To extend our findings on Τ cell responses to effector functions in vivo, we 
analysed DTH reactions in six congenie mouse strains (n=5). In agreement 
with the proliferation data, all strains showed a clear DTH response (Fig. 1). 
R/L ratio of ear thickness 
2.5 
1.5 
0,5 
B10A B10BR B10D2 B10G B10S C57BI 
Fig. 1. DTH was induced by infection of 1 μg GST/B-D (in E. coli produced Pfsl6 
encoded polypeptide fused to the C-terminus of the Schistosoma japonicum glutathione S-
transferase (GST)) into the right ear and 1 μ% GST as a control into the left ear of Pfsl6-
primed mice. Ear swelling was measured after 30 hours. Each group consists of 5 mice. 
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Fig. 2. Western blot analysis of protein extracts prepared from gametocytes, using sera 
raised against the hybrid particles Pfsl6-S,S in six different congenie strains of mice and 
a Pfsl6 specific monoclonal antibody 32F717. As negative control a normal mouse serum 
MO was used. 
Analysis of antì-Pfsló antibodies by ELISA, Western blot analysis and ISI 
The influence of MHC genes on the antibody production of Pfsl6 specific 
IgG was examined. Different H-2 congenie mice were immunised as 
described in Materials and Methods and anti-Pfsl6 specific IgG was 
determined by ELISA (Table 3) and gametocyte Western blot analysis (Fig. 
2). Using both assays, Pfsl6-specific IgG could be detected in all mouse 
strains, demonstrating the presence of at least one В cell epitope on Pfsl6. 
However, considerable differences in anti-Pfsl6 titers were measured in the 
ELISA, suggesting a МНС-dependence of the antibody-response. 
To investigate whether immunisation with the yeast hybrid particles could 
induce in all mouse strains protective immunity against sporozoite infection, 
the sera of the immunised mice were tested in a standard ISI assay using 
HepG2-A16 cells as described (18-20). The antisera reduced the infectivity 
of sporozoites by about 20-50% (Table 4), indicating that protective 
antibodies were produced by all mouse strains regardless of MHC. No 
correlation was found between ELISA titer and functionality as determined 
by the ISI assay. 
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Table 3. Mean levels of Pfsl6-specific IgG antibodies as measured by ELISA. Sera were 
tested at different dilutions, starting from 1:1000; results are expressed as titer, i.e. the 
highest serum dilution that gives an absorbance (at 450 nm) higher than 0.2. 
Strain Mean antibody titer 
balb/c 
C57B1/10 
B10.A 
B10.D2 
B10.BR 
B10.G 
B10.S 
< 1 
1 
1 
1 
1 
1 
1 
100 
16,000 
16,000 
4,000 
4,000 
4,000 
2,000 
Table 4. Effect of various mouse antisera on sporozoite invasion in HepG2-A16 cells. ISI 
is expressed as percentage invasion reduction as compared to the control serum from 
mouse balb/c. 
Strain Dilution ¡Wnv.sp. %ISI 
balb/c 
C57B1/10 
B10.A 
B10.D2 
B10.BR 
B10.G 
B10.S 
1 
1 
1 
1 
1 
1 
1 
100 
100 
100 
100 
100 
100 
100 
104 
78 
72 
68 
88 
58 
52 
0 
25 
31 
35 
18 
46 
52 
DISCUSSION 
The immune system controls parasite number and resistance to reinfection 
(21). Τ cells fulfill an important role in these events, either directly by 
mediating cellular responses or by regulating antibody production (16). 
Evidence more and more indicates that cell-mediated immune responses play 
an essential role in protective immunity against exo-erythrocytic 
developmental stages (2,6-15). Therefore, it is clear that the identification of 
epitopes that stimulate appropriate Τ cell activities will be critical to the 
development of an effective vaccine against malaria (11). An ideal vaccine is 
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able to elicit a long lasting immune response against the natural parasite, 
both at the Τ and В cell level (14) and the immune response should occur in 
all individuals, regardless of their genetic background (13) and be directed 
against epitopes that do not vary in the natural parasite population. The 
present results show that the highly conserved Pfsl6 antigen (22) of P. 
falciparum which is known to be able to induce antibody responses (17), also 
includes one or more Τ cell epitope(s), capable of stimulating Τ cells to 
proliferate upon challenge by purified recombinant Pfsl6 antigen, 
gametocytes or sporozoites. Furthermore, all six congenie mouse strains 
show a clear DTH response, demonstrating that the Pfsl6 antigen also 
includes Τ cell epitope(s) capable to establish Τ cell memory. Although 
restricted immune responses to particular P. falciparum antigens in certain 
strains of mouse have been observed (1,2,5,6,15), in this study all mice 
strains tested gave an antibody response to the Pfsl6 antigen as shown by 
Western blot analysis, regardless of their genetic background. However, 
considerable differences in anti-Pfsl6 titer were measured in the ELISA, 
suggesting a МНС-dependence of the antibody response. The present study 
also indicates that the yeast hybrid particles may be capable inducing 
sporozoite-neutralising activity in vivo because all six congenie mouse strains 
produce Pfsl6-specific antibodies that specifically diminish the in vitro 
sporozoite invasion of human hepatoma cells (HepG2-A16) by 20-50%. No 
correlation was found between ELISA titer and functionality as determined 
by the ISI assay. The inhibition capacity of the different antisera was, 
however, less than in a previous study (unpublished data) where sera from 
Pfsl6-S,S-immunised Balb/c mice could reduce the sporozoite invasion of 
human hepatoma cells by about 50-100%. The immunisation protocol, route 
of immunisation or adjuvants-choice may all have influenced the 
responsiveness to the Pfsl6 antigen. It is known that factors such as the 
route and frequency of immunisation, the selection of an appropriate 
adjuvant, and subsequent cellular interactions influence immune responses 
(23). 
Although the number of mice involved in the experiments was small, the 
observations strongly indicate that a vaccine consisting of the Pfsl6 antigen 
is very well capable to induce both humoral and cellular parasite-specific 
(sporozoite-neutralising) immunity in the genetically diverse human 
population. 
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CHAPTER 7 
Cross-reactive antigens between life cycle stages of 
Plasmodium falciparum 
Moelans, I.I.M.D. and Schoenmakers, J.G.G. 
Parasitology Today 8 (1992), 118-123 

The critical step towards the design of an effective antimalarial vaccine is to 
define the crucial epitopes on parasite antigens that are targets of a protective 
immune response by the human host (1,2). The immunological responses 
involved in protection have been difficult to define. It is known that 
immunity is predominantly stage-specific, and involves several mechanisms 
including antibodies, cell-mediated responses and cytokines. Vaccines should 
therefore be devised to generate a response against each individual stage and 
the ultimate, effective vaccine is likely to be a cocktail of immunogens each 
designed to have a specific protective role. 
The search for protective antigens has been complicated by the discovery of 
multiple crossreactivities between different parasite proteins. The 
cross-reactions among malaria antigens may be intramolecular or 
intermolecular (3). Intramolecular cross-reactions occur between different 
epitopes of one polypeptide. Intermolecular cross-reactions may involve 
antigens of different life-cycle stages or antigens of different strains of P. 
falciparum. Because one epitope may be involved in more than one 
cross-reaction, a network of cross-reacting epitopes results. 
Most of the intermolecular and intramolecular crossreactivities of 
Plasmodium falciparum are associated with the unusual repeating structures, 
that are a common feature of this organisms antigens (3,4,38). Repeats are 
widespread among P. falciparum antigens from different developmental 
stages despite various types of cellular organizations and apparently diver-
gent functions. Intramolecular cross-reactions have been best documented in 
the RESA polypeptide but they also occur in numerous other antigens where 
there is a degree of degeneracy in sequence repeats. The first intermolecular 
cross-reactions of P. falciparum to be reported involved the CS protein on 
sporozoites and an asexual bloodstage specific antigen, both of which reacted 
with a single monoclonal antibody (5). Since then, various forms of cross-
reactions amongst P. falciparum antigens have been observed {cf. Table 1). 
Cross-reactions are noted between different epitopes within one protein 
(Type I); between epitopes of different proteins of one life-cycle stage (Type 
II); between epitopes of different proteins that individually are expressed at 
different life-cycle stages (Type III). However, even another type of "cross-
reactivity" can occur when the same antigen is expressed in different life-
cycle stages (Type IV). 
Examples of type III and type IV crossreacting epitopes between different 
life cycle stages will be presented in this article and the importance of these 
cross-reactivities for the induction or modulation of immune protection will 
be discussed. Detailed information on Type I and II cross-reactions has been 
reviewed elsewhere (3,4). 
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Table 1. Levels of cross-reactivities amongst P. falciparum antigens 
Level of cross-reactivity Antigens involved 
Between different epitopes within 
one protein (type I) 
Between epitopes of different 
proteins of one life-cycle stage 
(type II) 
Between epitopes of different 
proteins of different life-cycle 
stages (type III) 
Expression of the same antigen in 
different life-cycle stages 
(type IV) 
RESA, CS-Protein, FIRA 
RESA and FIRA 
RESA and CARP 
CS protein and 5.1 
antigen 
Pfsl6, GLURP, RESA 
Type III Cross-reactions between asparagine-rich proteins 
Coppel et al. demonstrated that human antibodies that react with a blood 
stage antigen, Ag 5.1, also react with sporozoites (7). The 5.1 antigen (also 
referred to as exp-1, CRA or QF116) has a size of about 23 kDa and is 
present in blood stage parasites, in the parasitophorous vacuole membrane 
and in the cytoplasm of infected erythrocytes. In most isolates, the antigen 
contains two short amino acid sequences (Asn-Ala-Asn-Pro and Asn-A-
la-Asp-Pro) identical or related to the NANP sequence of the CS protein 
present on the sporozoite surface. Therefore, the observation that human 
antibodies against the 5.1 antigen react with sporozoites is most likely due to 
a cross-reaction between the 5.1 antigen and the CS protein (6-8). 
Ardeshir et al. recently showed that several immunogenic proteins from P. 
falciparum blood stage parasites share cross-reactive asparagine-rich 
antigenic determinants with each other and with the circumsporozoite protein 
(9). The asparagine residues were found either in clusters or in repeating 
sequences containing other amino acids. Some of these proteins, which 
contain cross-reactive epitopes, have similar apparent molecular weights to 
the proteins recognised by antibodies to ARP (220, 160, 98 and 52 kDa), 
CARP (36, 30, 15 kDa), 10b (36, 33 kDa) and CL2122 (177, 51 and 43 
kDa). Like other P. falciparum antigens, ARP contains tandemly repetitive 
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sequences, based on the tetrapeptide Asn-Asn-Asn-Met (10). Surprisingly, 
ARP is also rich in asparagine residues outside the tandem repeats. Because 
of the reactivity of anti-ARP antibodies with unfixed sporozoites, it is 
possible that some cross-reactivity may exist between ARP and CS protein, 
particularly because the latter also has a high asparagine content. However, 
anti-ARP antibodies and monoclonal antibodies (Mabs) against the CS 
protein-repeat do not compete with each other in binding to sporozoites, 
indicating that anti-ARP antibodies apparently do not react with an epitope 
encoded by the CS repeat. Interestingly, both CS protein and CL2122 
contain one copy of the 10b pentapeptide repeat Lys-Asn-Asn-Asn-Asn and 
might therefore share some cross-reactivity (11,12). 
Szarfman et al. has shown that antibodies against at least two epitopes on the 
CS protein of sporozoites, and 13 epitopes on at least seven proteins from 
asexual blood stage parasites, react with mature liver-stage schizonts (13). 
Liver merozoites are the parasites that will first invade red blood cells, and 
must synthesize proteins with critical functions that are vital for erythrocyte 
recognition, attachment and red blood cell entry. It is very likely that the 
proteins and corresponding epitopes on liver stages are similar to the 
analogous erythrocytic merozoite proteins. However, the reactivity of mature 
liver schizonts to anti-CS protein antibodies is probably not the result of 
cross-reacting proteins of asexual blood stages and of sporozoites, because 
the antibodies that were tested for reactivity to the CS protein did not react 
with infected red blood cells (13). Thus, although CS protein and proteins of 
mature liver stage parasites may share epitopes, the proteins may not be 
identical. Szarfman et al. (13) propose that immune responses against 
sporozoites or asexual blood stage parasites, induced after natural infection 
or immunization, could also act upon liver stage merozoites because of their 
shared epitopes, thereby reducing the first parasite load upon erythrocytes. 
Conversely, immune mechanisms induced by liver merozoites could act upon 
sporozoites and/or asexual blood stages and reduce the parasite load upon 
liver cells and/or erythrocytes. Liver stage-specific antigen-1 (LSA-1) shares 
some sequence homology with the P. falciparum CS protein cytotoxic 
lymphocyte (CTL) epitope (14,15). Therefore it is possible that CTLs may 
recognize both CS protein and LSA-1 epitopes and play an important role in 
the protection mediated by these cells. Kumar et al. (15) show that 
sporozoites can induce CS protein-specific CTL, and that in В10.BR mice 
the CTL réponse is restricted to a single peptide epitope from a variant 
region of the protein. It is possible that a vaccine could be developed that 
elicits either anti-LSA-1 antibodies that bind to LSA-1 surrounding newly 
released exoerythrocytic (ЕЕ) merozoites blocking their invasion of red 
blood cells, and CTLs that recognize LSA-1 epitopes expressed in 
association with class I molecules on the EE-infected hepatocyte membrane. 
125 
Ring-infected erythrocytic surface antigen (RESA) 
RESA is a polypeptide of 155 kDa that was originally found in asexual 
parasites (16,17). This antigen contains two blocks of tandemly repeated 
octapeptide sequences. The block at the C-terminus consists of eight amino 
acids (EENVEHDA) that is tandemly repeated five times of which the 
sequence EENV is repeated more than 30 times. The other block is located 
in the N-terminal part of the molecule and consists of an eleven amino acids 
repeat (DDEHVEEPTVA). Searches of sequence databases have revealed a 
number of proteins containing short sequences with homology to RESA (17), 
particularly those rich in acidic residues and which show with the glutamic 
acid repeats of RESA. 
Naturally-occurring human antibodies and rabbit antibodies to the RESA C-
terminal repeat, produced in Escherichia coli, also react with the N-terminal 
repeat, a reaction which also occurs when a Mab raised against the C-
terminal repeat is used (3). In this study about half of the Mabs were specific 
for the C-terminal repeat of RESA but the remainder reacted with the repeat 
structures at both the N- en C-terminal ends. 
In addition to the intramolecular cross-reactions amongst different epitopes 
within RESA, cross-reactions also occur between RESA and other blood 
stage antigens of P. falciparum (Table 2) including CARP, FIRA, 11.1 and 
332 (18). 
Table 2. Amino acid sequences forming potentially cross-reactive linear epitopes in 
different P. falciparum antigens. 
RESA: 
11.1: 
RESA: 
FIRA: 
RESA: 
CARP: 
E E N V E 
* * * * 
E E V V E 
E E H V 
* * * 
E E Ρ V 
E E N V E 
* * * 
E N V 
E N V E E 
* + * 
E V V Ρ E 
H N D A E E N V E H D A 
* * * 
E Τ V E 
V E 
* * 
V E 
S Τ 
* 
S w 
E V E E 
* * * 
I V E E 
L К 
* * 
L К 
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The basis for the isolation of the gene for CARP was the reactivity of the 
gene product with a human antibody preparation highly enriched in 
antibodies to RESA (19). The antigenic relationship between CARP and 
RESA was confirmed by the strong positive reaction of CARP with human 
antibodies that were affinity-purified using a synthetic peptide (EENVEHDA) 
representing one of the subunits of the C-terminal repeat of RESA. In 
addition, rabbit antibodies to this synthetic peptide reacted with CARP. This 
cross-reactivity could have been predicted from the sequence of CARP, since 
it contains two short amino acid stretches that are closely related to the C-
terminal repeat subunit of RESA. 
The 11.1 antigen possesses a large region composed of nine tandemly 
arranged amino acid repeats and is associated with the membrane of the 
schizont-infected red blood cell (20). The repeats of 11.1 are quite similar in 
sequence to the subunits of the C-terminal repeat region of RESA, i.e. 
EENVEENV and EENVEHDA. In a number of assays, polyclonal anti-
bodies to 11.1 reacted with RESA and vice versa. Partial sequencing and 
restriction mapping of the 11.1 gene revealed that it extends over 30 kb and 
contains 22 kb of a tandemly repeated, degenerate 27-bp sequence expressed 
as a nine amino acid repeat, as well as two shorter tandemly repeated 
sequences. The antigen encoded by this locus has been tentatively identified 
as a protein varying in size from 260-350 kDa among isolates. However, 
recent studies of Petersen et al. (21,22) indicate that the 11.1 locus encodes 
a protein of more than 1000 kDa. The authors suspect that cross-reactivity 
between 11.1 epitopes and epitopes of the 260 kDa protein, combined with 
the failure of the 1 Mda protein to enter the resolving gel and/or failure to 
electrophoretically transfer this protein under standard conditions, has led to 
the indirect identification of the 260 kDa protein as the gene product of the 
11.1 locus. Antibodies recognizing the 1 MDa protein cross-react with a 260 
kDa protein and with RESA. 
The 332 antigen is present in the late stages of asexual blood stage parasites 
and has an amino acid sequence containing a number of degenerated repeats 
and presents an antigenic determinant similar to those of other antigens, in 
particular 11.1 and RESA (23). Antibodies from human immune sera, that 
were affinity-purified using recombinant antigens of 332, 11.1 and RESA, 
revealed a high degree of cross-reactivity between the three antigens. As 
depicted in Table 3, these antigens are related by at least one antigenic 
structure, defined by the human Mab 33G2 (24). As 33G2 inhibits merozoite 
reinvasion with high efficiency, it defines an antigenic epitope of interest 
with regard to protective immunity and vaccine development. 
Mab 33G2 does not react with FIRA because cross-reactivity of FIRA is 
shared with the N-terminal repeat region of RESA, a region not recognized 
by 33G2 (25). The cross-reactivity of RESA with CARP probably involves 
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short sequences of homology in the latter antigen and this would explain why 
33G2 also does not react with this antigen. 
Cross-reactivity between antigens of sexual and asexual stage parasites 
The monoclonal antibody 33G2 also reacts with P. falciparum gametocytes 
as detected by immunofluorescence (27,28). Interestingly, another mouse 
MAb, 9B11, raised against P. falciparum gametocytes, predominantly 
recognizes a 150 kDa polypeptide on immunoblots from all developmental 
stages of the erythrocytic cycle of P. falciparum, including gametocytes (29). 
The electrophoretic mobility of this polypeptide is identical to that of RESA, 
on the asexual parasite, and 9B11 binds to synthetic and recombinant pep-
tides [(EENV)2] derived from RESA. These results were also confirmed with 
rabbit sera to a synthetic peptide (EENV)2 or to a recombinant protein 
EENVEHDA derived from RESA indicating that there exists an extensive 
cross-reactivty between sexual and asexual blood stage antigens. 
Besides RESA, antigen 11.1 is also present in gametocytes and is in the 
range of 260-350 kDa (30). Antibodies specific for the 11.1 antigen react 
with granules within and around the gametocyte-infected red blood cell as 
seen with immunogold labeling. 
GLURP, an antigen expressed in all stages of the parasite life cycle in the 
vertebrate host, was recently described by Borre et al. (31). Their data 
indicate that the GLURP gene is conserved in nine geographically different 
isolates and that it is highly immunogenic. The GLURP gene codes for a 220 
kDa glutamate-rich protein, which contains two repeat regions. Immunogold 
electron microscopy has shown that the GLURP antigen is expressed in the 
liver stage and in the asexual and sexual stages. The structural organization 
of GLURP mostly resembles that of RESA, which also has 2 conserved 
repeat regions. However, although both proteins are glutamate-rich they 
share no sequence homology. Despite the fact that antibodies raised against 
RESA also recognize a protein of 210 kDa in an immunoblot assay, 
antibodies against GLURP do not recognize RESA. 
Recently, we reported the presence of a highly conserved 16 kDa protein, 
Pfsl6, in both sexual stage parasites and sporozoites (32,33). Rabbit antisera 
raised against a synthetic peptide and against recombinant fusion proteins 
recognize a 16 kDa antigen in protein extracts of gametocytes, 
macrogametes/zygotes and sporozoites by Western blot analysis. By 
immuno-electron microscopy, Pfsl6 could also be clearly visualized on the 
surface of macrogametes and sporozoites. Moreover, Pfsl6 mRNA has now 
been detected in gametocytes, macrogametes and sporozoites (Moelans, 
I.I.M.D., unpublished). 
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Table 3. Reactivity of human Mab 33G2 with synthetic peptides 
Antigen Peptide 
11.1 (PEEV/LVEEV/IV)2GK 
332 Y(SVTEEIAEE)2 
RESA (EENV)4 
Although the precise biological function of the 16 kDa protein has yet to be 
established, preliminary investigations indicate the involvement of Pfsl6 as a 
sporozoite binding factor in hepatocyte invasion. This is the first description 
of an antigen that is expressed in the sexual stages of the parasite and in 
sporozoites. Pfsl6 may be a potential candidate for an infection/transmission 
blocking vaccine. 
A sexual stage specific antigen, Pfs25, shares structural motifs with the 
merozoite surface protein MSA1 (34,35). Both antigens contain Epidermal 
Growth Factor (EGF)-like domains with a characteristic spacing of cysteine 
and a glycine residue: [Cysl-X^-tCysl-X^-tCysJ-Xg.n-fCysl-X-tCysl-Xs.,-
Gly-X2-[Cys] where X represents other amino acid residues. Proteins 
containing these structural motifs are notably involved in receptor binding or 
other cell-surface interactions. The importance of this part of MSA1 during 
invasion is highlighted by the ability of antibodies against this region to 
inhibit P. falciparum growth in vitro (35). Albeit both antigens share EGF-
like domains, to date no cross-reactivities have been reported. 
Cross-reactive antigens and vaccine development 
The immune responses to plasmodia are very complex and differ from the 
immune responses to viral or bacterial infections in several ways. Protective 
immunity develops only after the indivual is exposed to many infections over 
several years. This may reflect infection by multiple strains of parasites 
expressing variant antigens and/or strain differences, or it may reflect the 
parasites' immune evasion strategies. The respective roles of humoral- and 
cell-mediated immunity and non-specific immune responses in the 
development of acquired immunity have still to be elucidated (36). Although 
it is clear that humans and other mammalian hosts can develop protective 
immune responses, the protracted period needed to achieve full protection 
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from clinical symptoms suggests that plasmodia, like many other parasites, 
have developed mechanisms of partially escaping the protective effector 
mechanism of their hosts (37,38). Individuals who have high levels of 
antimalarial antibodies in their serum may still be susceptible to attacks of 
malaria. Either these sera lack antibody specificities that are critical for 
resistance, have a too low affinity or have the wrong isotype to confer 
protection. The search for protective antigens has been complicated by the 
discovery of multiple cross-reactivities between different parasite proteins. 
Anders (3) has proposed that the presentation of multiple cross-reacting 
epitopes to the immune system will impair the development of protective 
immune responses. This could occur either by absorption of antibodies on 
antigens non-essential for the survival of the parasite or by induction of 
antibodies of low affinity inefficient in parasite elimination. 
Antibody response to sporozoites appears to be directed almost entirely 
towards the repetitive domain of the CS protein, indicating that this is a 
single immunodominant epitope recognized by naturally induced antibodies. 
Conversely, antibodies to adjacent non-repeat epitopes of the CS protein and 
other repeat-containing proteins is much less prevalent. Similar types of 
immunodominance is exhibited by RESA. However, the level of antibodies 
to these repeats has not always correlated with protection (38-40). The 
marked hypergammaglobulinemia of non-protected individuals is probably 
the result of overstimulation of ineffectual B-cell responses, which leads to 
less efficient responses to important antigens. This proliferation may be 
increased by the fact that a number of antigens contain epitopes of 
sufficiently similar structure to allow cross-reaction with particular 
antibodies. These epitopes may be on different molecules or on the same 
one. The presence of a large number of closely related epitopes is thought to 
interfere with the process of affinity maturation, whereby only B-cells 
producing the highest affinity antibodies to a particular epitope are selected 
to proliferate after the initial antigen binding. The cross-reactions may thus 
assist the parasite by diverting the immune response towards irrelevant 
epitopes in a sort of "smokescreen" effect (3,4). Why should the parasite 
present highly immunogenic antigens on its surface that induce protective 
immunity (38)? While inducing low-grade non-neutralising antibodies, the 
repeat can be immunodominant, and will suppress the formation of 
antibodies to important adjacent areas on the same or on different molecules. 
The cross-reactivities between CS protein, liver stage antigens and blood 
stage antigens may be a mechanism which enables the parasite to evade 
immunity by presenting an extensive network of cross-reactive epitopes to 
the host over a longer period of time, thus preventing affinity maturation of 
the response to less immunogenic, protective epitopes. In fact, the 
extracellular sporozoite is present in the circulation for a very short time, but 
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asexual stages persist for long periods. While the host is parasitaemic, cross 
reactive responses are boosted, lessening the likelihood of successful 
protective immune responses. In the case of RESA the cross-reactive 
immunodominant response persists throughout the sexual stages, probably 
suppressing the formation of transmission-blocking antibodies. 
Although it is generally accepted that the parasite can escape from a 
protective immune response when it transforms from one stage of its life 
cycle to the next, the presence of Pfsl6, GLURP, 11.1 and RESA in 
different life cycle stages indicate that the different developmental stages may 
share the same epitopes or even the same antigens. The parasite can escape 
from a protective immune response through immunodominant epitopes 
present on different life cycle stages. Therefore, cross-reactive 
epitopes/antigens may either perform an immunological or a functional role. 
All of these cross-reactivities have important implications for the 
development of a vaccine based on surface proteins. Candidate molecules 
must be identified by functional rather than immunological criteria. 
However, the propensity of the malarial parasite to induce large amounts of 
irrelevant "smokescreen" antibodies against variable immunodominant 
regions of a number of antigens has complicated the search for protective 
epitopes. The immunogenicity of essential regions may have to be increased 
by suitable presentation or by molecular modifications, enabling the 
induction of protective immune responses. 
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CHAPTER 8 
Summary 

Malaria is an infectious disease transmitted by mosquitoes and is caused by 
parasitic protozoa of the genus Plasmodium. More than 400 million people 
are estimated to be infected and each year the disease causes up to 2 million 
deaths of which the majority are children. Four species of Plasmodium infect 
man, i.e. P. vivax, P. ovale, P. malariae and P. falciparum. The first three 
species cause moderate to severe illness and are seldom fatal. The fourth, 
i.e. P. falciparum, to which the greatest attention is paid in investigations, 
causes much more serious and progressive illness and frequently leads to 
coma and death. 
From the mid-seventies strategies to control malaria have been directed at the 
development of effective vaccines. Four different types of malaria vaccines, 
directed to discrete life cycle stages of the parasite, are under development, 
namely those targeted to the sporozoites, the liver stages, the blood stages 
and one that limits transmission of malaria by immune interference with the 
development of sexual stages in the mosquito host. Development of an 
effective malaria vaccine has been, however, much slower than originally 
was anticipated. The major obstacles to produce an effective malaria vaccine 
are: (1) the impossibility to use attenuated or killed parasite preparations as a 
vaccine because of problems associated with parasite supply, the danger of 
transmitting other pathogens with the inoculum and the development of 
autoimmunity due to the almost inevitable contamination of host pathogens in 
the preparation; (2) the complexity of the host's immune responses to 
Plasmodia; (3) the parasite's complex life cycle; (4) antigenic diversity in 
malaria parasites; (5) the multiple crossreactivities between different parasite 
antigens. Fortunately, the rapid advances in recombinant DNA technology, 
peptide chemistry and immunology have in theory provided powerful tools 
and novel approaches to achieve the development of an effective malaria 
vaccine. However, the unusual characteristics of the P. falciparum genome, 
particularly its very high Α-T content, make P. falciparum DNA extremely 
difficult to handle in recombinant DNA technologies. Furthermore, frequent 
difficulties were encountered in the heterologous expression of P. falciparum 
antigens because of unusual codon bias: A or Τ preferred in second and third 
nucleotide position. 
In this thesis studies with the aim to develop a vaccine against the human 
malaria parasite P. falciparum are presented. The strategy /methodology used 
for the isolation of a vaccine candidate is described in chapter 2. In this 
chapter we report the isolation of a P. falciparum cDNA clone, which 
contains a copy of the intron-less gene Pfsl6. The gene is transcribed at very 
high rates in the sexual stages but not in the asexual erythrocytic stages of 
the parasite. From its nucleotide sequence it is deduced that gene Pfsl6 
encodes a protein of 157 amino acids (M
r
= 16,607). The amino acid 
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sequence of this 16 kDa protein contains a putative signal peptide at the N-
terminus, a short hydrophobic membrane anchor in the second half of the 
protein molecule and a cytoplasmic (hydrophilic) region at the C-terminus; 
these features are consistent with the structure of an integral membrane 
protein. Rabbit antisera raised against a synthetic peptide encompassing 
amino acids 31-47 of the Pfsl6 antigen and against recombinant fusion 
proteins produced in E. coli recognise the 16 kDa antigen in protein extracts 
of gametocytes, macrogametes/zygotes and sporozoites by Western blot 
analysis. The rabbit antisera also reacted with gametocytes, gametes and 
sporozoites in a standard immunofluorescence assay. By immunoelectron 
microscopy the Pfsl6 antigen could clearly be visualised in cells of the 
sexual stages and at the surface sporozoites, whereas the antigen was not 
detectable in the asexual erythrocytic stages of the parasite. The studies 
described in chapter 2 all indicate that the Pfsl6 antigen is an attractive 
antigen to study its suitability for the development of a transmission-blocking 
and/or sporozoite-neutralising vaccine. 
In chapter 3 by one- and two-dimensional Western blot analysis, using two 
Pfsl6 specific monoclonal antibodies, it is demonstrated that the 16 kDa 
proteins found to be present in gametocytes and sporozoites are identical. 
RT-PCR analysis of affinity-captured RNA revealed the presence of Pfsl6 
specific mRNA in both gametocytes and sporozoites. By Northern blot 
analysis it is demonstrated that the Pfsl6 gene is expressed in sporozoites via 
two mRNA species with sizes of 1.4 and 3 kb respectively, while in 
gametocytes and macrogametes/zygotes the gene is only expressed via an 
mRNA species with a size identical to that of the smallest found in 
sporozoites. The possible molecular mechanism(s) underlying the differential 
expression of the Pfsl6 gene are discussed. 
Since antigenic diversity in other P. falciparum candidate antigens severely 
has hampered the development of an effective vaccine, the amino acid 
sequence diversity of the Pfsl6 antigen in P. falciparum clones derived from 
isolates collected from different geographic areas (Brazil, Liberia, Ghana, 
Honduras, Malaysia and Indochina) has been analysed (chapter 4A). From 
the data obtained it can be concluded that the amino acid sequence diversity 
of the Pfsl6 antigen is almost negligible, indicating that significant 
alterations of the amino acid sequence of the Pfsl6 antigen are probably 
deleterious to the parasite. 
A gene, named Prsl6, highly homologous to gene Pfsl6 was found to be 
present in P. reichenowi, a chimpanzee malaria parasite that is evolutionary 
related to P. falciparum. Comparison of genes Prsl6 and Pfsl6 reveals that 
they are highly homologous at both the nucleotide (96%) and amino acid 
(94%) sequence level. In chapter 4B the differences between the Prsl6 and 
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Pfsl6 antigens are discussed in relation to differences in host-sporozoite 
interaction and/or invasion. 
For basic research and vaccine development sufficient amounts of the Pfsl6 
antigen can not be isolated from P. falciparum. Therefore, recombinant 
Pfsl6 sequences and peptides thereof have been produced in heterologous 
pro- and eukaryotic expression systems. In chapter 5A studies are described 
concerning the expression of Pfsl6 sequences in yeast and mammalian cells. 
To obtain more information on the precise biological function of the Pfsl6 
antigen and to explore its potential role in hepatocyte invasion, immunisation 
studies were performed using recombinant Pfsl6 vaccinia virus and virus-
like particles composed of chimeric fusion protein consisting of the hepatitis 
В surface antigen (HBsAg) and Pfsl6 produced in yeast. Animals vaccinated 
with yeast hybrid particles and/or recombinant vaccinia virus produced Pfsl6 
specific antibodies. These antibodies showed no transmission-blocking 
activity, but they efficiently diminished or abolished in vitro invasion of 
sporozoites into human HepG2-A16 cells and primary human hepatocytes. 
The studies described in chapter 5A clearly demonstrate that the Pfsl6 
antigen is expressed in cells of the sexual stages and in exo-erythrocytic 
stages of P. falciparum and probably acts as a sporozoite binding factor in 
hepatocyte invasion. 
Although it was demonstrated that large quantities of recombinant Pfsl6 
fusion protein produced as virus-like in yeast could be purified and that 
immune responses could be induced in vaccinated animals, the recombinant 
protein is not suitable for serological studies, because of the likely presence 
of HBsAg specific antibodies in human sera. Therefore, we have constructed 
a new system for the large-scale heterologous synthesis and one-step 
purification of antigen Pfsl6 in E. coli. The recombinant protein consists of 
the authentic amino acid sequence of native Pfsl6 fused at its carboxy-
terminal end to a poly-histidine tag. In chapter 5B it is demonstrated that 
large amounts of this recombinant Pfsl6 protein easely can be purified by 
nickel affinity chromatography and that the recombinant protein is 
appropriate for large-scale epidemiological studies to demonstrate the 
presence of Pfsl6 specific antibodies. 
Since immunological studies more and more indicate that both humoral and 
cellular immune responses play an important role in the protection against 
sporozoite-induced malaria, studies were undertaken to determine whether 
the Pfsl6 antigen can induce humoral as well as cellular immune responses. 
For this purpose six different congenie mice strains were immunised with the 
virus-like hybrid particles produced in yeast. The results of this study are 
described in chapter 6. Specific antibody production, lymph node cell 
proliferation and Delayed Type Hypersensitivity response was observed in all 
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six congenies, regardless of МНС. All sera diminished the in vitro invasion 
of HepG2-A16 cells by sporozoites. 
The search for protective antigens has been complicated by the discovery of 
multiple 'cross-reactivities' between different parasite proteins. In chapter 7 
various forms of cross-reactions amongst P. falciparum antigens are 
described. The consequences of these cross-reactions for the development of 
an effective malaria vaccine are also discussed. 
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CHAPTER 9 
Samenvatting 

Malaria is een infectieziekte die wordt overgedragen door muggen en wordt 
veroorzaakt door parasitaire protozoa van het genus Plasmodium. Jaarlijks 
worden er naar schatting 400 miljoen mensen geïnfecteerd met de malaria 
parasiet en ongeveer 2 miljoen mensen, met name kinderen, overlijden ten 
gevolge van malaria. Vier Plasmodium species zijn in staat om de mens te 
infecteren: P. vivax, P. ovale, P. malariae and P. falciparum. De eerste drie 
species veroorzaken matige tot ernstige ziektebeelden maar zijn zelden 
dodelijk. Een P. falciparum infectie daarentegen leidt meestal tot veel 
ernstiger ziekteverschijnselen en heeft vaak een dodelijke afloop. 
Sedert het midden van de zeventiger jaren wordt veel aandacht besteed aan 
de ontwikkeling van een malaria vaccin. Er wordt onderzoek gedaan naar 
vier verschillende typen, die gericht zijn tegen diverse stadia van de 
levenscyclus van de malaria parasiet. Momenteel wordt er gewerkt aan 
vaccins die zijn gericht tegen de sporozoïeten, de leverstadia, de asexuele 
bloedstadia en tegen de sexuele vormen. 
De ontwikkeling van een malaria vaccin verloopt echter veel langzamer dan 
aanvankelijk werd verwacht. De belangrijkste problemen bij de ontwikkeling 
van een effectief malaria vaccin zijn: (1) de onbruikbaarheid van afgezwakte 
of dode parasiet preparaten als gevolg van problemen met de levering van 
parasieten, de mogelijke aanwezigheid van andere pathogenen in het 
inoculum en de mogelijke ontwikkeling van autoimmuniteit door een vrijwel 
onvermijdelijke contaminatie van de parasieten preparaten met gastheer 
antigenen; (2) de complexiteit van de immuun responsen van de gastheer die 
gericht zijn tegen Plasmodia; (3) de ingewikkelde levenscyclus van de 
parasiet; (4) de antigene diversiteit die aanwezig is in malaria parasieten; (5) 
de aanwezigheid van veelvuldige "kruis-reakties" tussen verschillende 
parasiet antigenen. 
De snelle vooruitgang in de recombinant DNA technologie, peptide chemie 
en immunologie zouden in theorie een belangrijke bijdrage kunnen leveren 
aan de snelle ontwikkeling van een effectief malaria vaccin. Helaas zorgen 
de ongebruikelijke eigenschappen van het P. falciparum genoom, met name 
het hoge A-T gehalte, ervoor dat P. falciparum DNA extreem moeilijk te 
hanteren is in de recombinant DNA technologie. Bovendien worden er grote 
moeilijkheden ondervonden bij de heterologe expressie van P. falciparum 
antigenen als gevolg van een ongewoon codon gebruik: P. falciparum heeft 
een voorkeur voor een A of een Τ in de tweede en derde nucleotide positie 
van een codon. 
In dit proefschrift wordt gerapporteerd over studies die gericht zijn op de 
ontwikkeling van een vaccin tegen de humane malaria parasiet P. 
falciparum. De strategie/methodologie die werd gebruikt voor de isolatie van 
een vaccin kandidaat wordt beschreven in hoofdstuk 2. Hierin wordt 
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gerapporteerd over de isolatie van een P. falciparum cDNA kloon, die een 
kopie bevat van het intronloze gen Pfsl6. Dit gen wordt veelvuldig 
getranscribeerd in de sexuele stadia van de parasiet, maar niet in de asexuele 
bloedstadia. Uit de nucleotide sequentie kan afgeleid worden dat het Pfsló 
gen codeert voor een 157 aminozuren lang eiwit (Mr= 16,607). De 
aminozuur volgorde van dit 16 kDa eiwit bevat een signaal peptide aan het 
N-terminale uiteinde, een kort hydrofoob membraan anker in de tweede helft 
van het eiwit en een hydrofiele cytoplasmatische regio nabij de C-terminus; 
deze eigenschappen komen overeen met de struktuur van een membraan 
eiwit. Antisera die opgewekt zijn in konijnen tegen een synthetisch peptide 
van het Pfsl6 antigeen (aminozuren 31-47) en tegen recombinante Pfsló 
fusie-eiwitten, geproduceerd in E. coli, herkennen een 16 kDa antigeen in 
eiwit extracten van gametocyten, macrofagen/zygoten en sporozoïten in een 
Western blot analyse. Deze antisera reageren ook met gametocyten, gameten 
en sporozoïeten in een standaard immunofluorescentie assay. Met behulp van 
immuno-elektronen microscopie studies kon het Pfsló antigeen duidelijk 
worden aangetoond in cellen van de sexuele stadia en aan het oppervlak van 
sporozoïeten. Het antigeen was echter niet detecteerbaar in de asexuele stadia 
van de parasiet. De resultaten die beschreven worden in hoofdstuk 2 
suggereren dat het Pfsló antigeen een potentiële kandidaat is voor de 
ontwikkeling van een transmissie-blokkerend en/of sporozoïet-neutralizerend 
vaccin. 
In hoofdstuk 3 wordt met behulp van één- en twee-dimensionale Western 
blot analyses, waarbij gebruik wordt gemaakt van twee Pfsló-specifieke 
monoclonale antilichamen, aangetoond dat de 16 kDa eiwitten die aanwezig 
zijn in gametocyten en sporozoïeten identiek zijn. RT-PCR analyse van 
affiniteits-gezuiverd mRNA wijst bovendien op de aanwezigheid van Pfsló 
specifiek mRNA in zowel gametocyten als sporozoïeten. Met behulp van 
Northern blot analyse wordt aangetoond dat het Pfsló gen tot expressie komt 
in sporozoïeten via twee mRNA species van 1.4 en 3 kb respectievelijk, 
terwijl in gametocyten het gen tot expressie komt via een mRNA species die 
even groot is als het kleinste Pfsló transcript in sporozoïeten. Tot slot 
worden de moleculaire mechanismen die ten grondslag kunnen liggen aan de 
differentiële expressie van het Pfsló gen besproken. 
Aangezien in het verleden de antigene diversiteit in andere P. falciparum 
antigenen de ontwikkeling van een effectief malaria vaccin aanzienlijk heeft 
belemmerd, werd de aminozuur sequentie diversiteit van het Pfsló antigeen 
in P. falciparum klonen geanalyseerd afkomstig van isolaten geïsoleerd in 
verschillende geografische gebieden (Brazilië, Liberie, Ghana, Honduras, 
Maleisië en Indochina) (hoofdstuk 4A). Uit de verkregen data kon worden 
geconcludeerd dat de aminozuur sequentie diversiteit in het Pfsló antigeen 
verwaarloosbaar klein is, hetgeen aangeeft dat significante veranderingen in 
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de aminozuur volgorde van het Pfsl6 antigeen waarschijnlijk noodlottig 
zouden zijn voor de parasiet. 
Een gen, genaamd Prsló, dat een grote nomologie heeft met het Pfsl6 gen 
werd aangetoond in P. reichenowi, een chimpanzee malaria parasiet die 
evolutionair verwant is aan P. falciparum. Een vergelijking van de Pfsló en 
Prsló genen toont aan dat er zowel op nucleotide (96%) als op aminozuur 
(94%) sequentie niveau een grote mate van homologie bestaat tussen beide 
genen. In hoofdstuk 4B worden de verschillen tussen de Prsló en Pfsló 
antigenen besproken in relatie tot de verschillen in gastheer-sporozoïet 
interaktie en/of invasie. 
Voor basaal wetenschappelijk onderzoek en vaccin ontwikkeling kan niet 
voldoende Pfsló antigeen worden geïsoleerd uit de parasiet. Daarom zijn er 
recombinante Pfsló sequenties gesynthetiseerd met behulp van heterologe 
pro- en eukaryotische expressie-systemen. In hoofdstuk 5A worden studies 
beschreven die betrekking hebben op de expressie van Pfsló sequenties in 
gist en zoogdier cellen. Om meer informatie te krijgen over de precieze 
biologische functie van het Pfsló antigeen en om de mogelijke rol tijdens 
hepatocyt invasie te onderzoeken, zijn immunisatie studies uitgevoerd 
waarbij gebruik is gemaakt van recombinant Pfsló vaccinia virus en virus-
achtige partikels die zijn geproduceerd in gist en die chimere fusie-eiwitten 
bevatten bestaande uit het hepatitus В oppervlakte eiwit (HBsAg) en Pfsló. 
Proefdieren die waren geïmmuniseerd met recombinant vaccinia virus en/of 
hybride gist partikels produceerden Pfsló specifieke antilichamen. Deze 
antilichamen vertoonden geen transmissie-blokkerende activiteit, maar waren 
in staat de in vitro invasie van sporozoïeten in humane HepG2-A16 cellen en 
primaire humane hepatocyten te verminderen of zelfs helemaal te remmen. 
De onderzoeksresultaten die beschreven worden in hoofdstuk 5A tonen 
duidelijk aan dat het Pfsló antigeen wordt geproduceerd in de sexuele en 
exo-erythrocytaire stadia van de parasiet P. falciparum en dat het eiwit 
mogelijkerwijze de functie vervult van een sporozoïet bindende factor tijdens 
de hepatocyt invasie. 
Ondanks het feit dat grote hoeveelheden recombinant Pfsló fusie-eiwit kan 
worden geproduceerd in de vorm van virus-achtige partiels in gist cellen en 
dat een adequate immuun respons geïnduceerd kon worden in gevaccineerde 
proefdieren, is het recombinante gist produkt niet geschikt voor serologische 
studies, omdat HBsAg-specifieke antilichamen aanwezig kunnen zijn in 
humane sera. Daarom is een nieuw systeem ontwikkeld voor heterologe 
expressie en één-staps zuivering van het Pfsló antigeen in E. coli. Het 
recombinante E. coli eiwit bevat de authentieke aminozuur volgorde van het 
natieve Pfsló antigeen en is gefuseerd aan het C-terminale uiteinde met een 
poly-histidine staart. In hoofdstuk 5B wordt aangetoond dat grote 
hoeveelheden van dit recombinante Pfsló eiwit op een eenvoudig wijze 
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kunnen worden opgezuiverd met behulp van nikkel affiniteits chromatografie 
en dat het recombinante eiwit geschikt is voor gebruik tijdens grootschalige 
epidemiologische studies om de aanwezigheid van Pfsl6-specifieke 
antilichamen aan te tonen. 
Aangezien immunologische studies regelmatig aangeven dat zowel humorale 
als cellulaire immuun responsen een belangrijke rol spelen bij de 
bescherming tegen malaria, zijn experimenten uitgevoerd om uit te zoeken of 
het Pfsló antigeen zowel humorale als cellulaire immuun responsen kan 
induceren. Voor dit doel zijn zes verschillende congene muizestammen 
geïmmuniseerd met recombinante Pfsló-bevattende gist partikels. De 
resultaten van deze studie worden gepresenteerd in hoofdstuk 6. Een 
specifieke antilichaam respons, Τ cel proliferatie en DTH respons is 
waargenomen in alle congene stammen, ongeacht de MHC. Bovendien 
blijken alle antisera in staat om de sporozoïten invasie van HepG2-A16 
cellen te remmen. 
Het zoeken naar "beschermende" antigenen wordt bemoeilijkt door 
veelvuldige kruis-reacties tussen verschillende parasiet eiwitten. In hoofdstuk 
7 worden de verschillende vormen kruis-reacties beschreven en de 
consequenties van deze kruis-reacties voor de ontwikkeling van een effectief 
malaria vaccin. 
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CURRICULUM VITAE 

CURRICULUM VITAE 
De schrijfster van dit proefschrift werd op 18 juli 1963 te Etterbeek (B) 
geboren. Na het behalen van het Europese baccalaureaatsdiploma 
Gymnasium В aan de Europese School te Luxemburg (L) werd in 1981 
begonnen met de studie Biologie aan de Katholieke Universiteit Nijmegen. In 
1985 werd het kandidaatsexamen Biochemie (B4) behaald. De 
doctoraalexamens Biologie en Scheikunde (hoofdvakken Farmacologie en 
Moleculaire Biologie, bijvak Chemische Cytologie) werden in augustus 1988 
afgelegd. 
Van 1 september 1988 tot 1 september 1992 was zij als Assistente in 
Opleiding verbonden aan de afdeling Moleculaire Biologie van de Katholieke 
Universiteit Nijmegen, waar onder begeleiding van Prof. Dr. R.N.H. 
Konings en Prof. Dr. J.G.G. Schoenmakers het in dit proefschrift 
beschreven onderzoek werd uitgevoerd. In november 1991 werd haar het dr. 
I.B.M. Frye stipendium uitgereikt. Van 1 januari 1993 tot 1 november 1994 
was zij als toegevoegd onderzoekster werkzaam bij de afdeling 
Besmettingsleer van de Universiteit Utrecht. Sinds 1 november 1994 is zij 
als wetenschappelijk medewerkster in dienst bij de afdeling Parasitologie van 
de firma Janssen Pharmaceutica te Beerse, België. 
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